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1. INTRODUCTION 
1.1 BREAST CANCER INCIDENCE, CLASSIFICATION AND THERAPEUTIC 
OPTIONS 
1.1.1 INCIDENCE AND MORTALITY OF BREAST CANCER WORLDWIDE AND IN EUROPE 
According to the Global Cancer Observatory 18,078,957 new cancer cases occurred 
worldwide in 2018 of which 2,088,849 cases were breast cancer (Ferlay et al., 2019; 
IARC, 2018). Therefore, breast cancer is the second most common cancer type after 
lung cancer.  
In women, breast cancer has the highest incidence with 24.2% and is the leading 
cause of cancer deaths with 626,679 cases in 2018 (Fig.1). 
 
  
Figure 1. Estimated number of new cases of cancer in women worldwide in 2018 according to Globocan 
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In Europe 74.4 of 100,000 women develop breast cancer of whom 14.9 die due to this 
disease (Fig.2).  
 
Figure 2. Estimated incidence and mortality rates in Europe of different cancer types in women in 2018 
according to Globocan 2018, World Health Organization. 
 
These statistics clearly show, that breast cancer is still a huge threat for women 
worldwide, especially in developed countries.  
1.1.2 DIFFERENT SUBTYPES OF BREAST CANCER AND THERAPEUTIC OPTIONS 
Even though breast cancer is a serious disease in general, it is important to 
differentiate between breast cancer subtypes for prognostic and therapeutic reasons. 
In general, breast cancer can be classified according to histological and molecular 
characteristics. Here, the differentiation of molecular subtypes was of special interest. 
Nowadays, four different breast cancer subtypes are known: Luminal A, Luminal B, 
Her2+ and basal like/triple-negative breast cancer (TNBC) (American-Cancer-Society, 
2019; Cardoso et al., 2019; Harbeck et al., 2014; Li et al., 2015; Prat et al., 2015; 
Sorlie, 2016; Sorlie et al., 2001; Vuong et al., 2014).  
1. INTRODUCTION 
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1.1.2.1 LUMINAL A BREAST CANCER 
The subtype Luminal A is the most common one with approximately 73% of all mamma 
carcinoma, and the molecular phenotype is characterized by high expression levels of 
the hormone receptors estrogen receptor (ER) and progesterone receptor (PR) 
(American-Cancer-Society, 2019; Prat et al., 2015). However, the human epidermal 
growth factor 2 (Her2) is not expressed in this molecular subtype. The Luminal A breast 
cancer subtype is known to be less aggressive and has therefore the most favorable 
prognosis. Usually, this phenotype is well treatable with anti-hormonal therapy like 
selective estrogen receptor modulators (SERMs) e.g. tamoxifen, selective estrogen 
receptor degraders (SERDs) e.g. fulvestrant or aromatase inhibitors (AIs) e.g. letrozol 
(Cardoso et al., 2019). Chemotherapy can be considered as addition to endocrine 
therapy in cases of high tumor burden. 
1.1.2.2 LUMINAL B BREAST CANCER 
Similar to Luminal A breast cancer, this breast cancer subtype expresses high levels of 
estrogen receptor. Additionally, Luminal B breast cancer is defined by the expression 
of Ki67, leading to exaggerated cell proliferation and thus increased aggressiveness 
compared to Luminal A breast cancer (American-Cancer-Society, 2019; Cardoso et al., 
2019). Her2 can also be overexpressed in this breast cancer subtype, however this is 
not a mandatory characteristic. According to the European Society for Medical 
Oncology (ESMO) guidelines these tumors should be treated with endocrine therapy 
like SERMs, SERDs or AIs and chemotherapy. Depending on the Her2 status 
trastuzumab can also be added to the therapeutic regimen (Cardoso et al., 2019). In 
the US this phenotype is present in approximately 11% of all breast cancer patients 
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1.1.2.3 HER2 OVEREXPRESSING (HER2+) BREAST CANCER 
In contrast to the Luminal breast cancer subtypes described above, this phenotype is 
expressing neither estrogen, nor progesterone receptor and is therefore hormone 
receptor negative. Instead, in this subtype Her2, a receptor tyrosine kinase, is 
overexpressed causing increased cell proliferation and hence tumor growth as well as 
aggressiveness. Therefore, this breast cancer subtype had the worst prognosis in the 
past. With the development of targeted therapy like therapeutic antibodies e.g. 
trastuzumab and pertuzumab, small molecule inhibitors (SMIs) e.g. lapatinib and 
neratinib and antibody drug conjugates (ADCs) e.g. trastuzumab-emtansine (T-DM1) 
the patient outcome can be improved (Cardoso et al., 2019; Coates et al., 2015). 
According to the S3 guidelines, Her2+ tumors should moreover be treated with 
chemotherapy including taxanes e.g. paclitaxel and anthracyclines e.g. doxorubicin 
(Leitlinienprogramm-Onkologie (Deutsche Krebsgesellschaft, 2020).  
In the US this tumor phenotype is prevalent in approximately 4% of all breast cancer 
patients, in Europe Her2+ breast cancer accounts for about 15% of all mamma 
carcinoma depending on the molecular test cut-offs (American-Cancer-Society, 2019; 
Cardoso et al., 2019; Leitlinienprogramm-Onkologie (Deutsche Krebsgesellschaft, 
2020). 
1.1.2.4 TRIPLE-NEGATIVE BREAST CANCER 
This breast cancer subtype is characterized by the absence of estrogen, progesterone 
and Her2 receptor and is therefore called triple-negative breast cancer (TNBC). 75-
80% of all TNBC tumors have a basal-like phenotype (American-Cancer-Society, 2019; 
Cardoso et al., 2019; Prat et al., 2013). Hence, the endocrine or Her2-targeted therapy 
is not effective in this tumor entity. The current standard of care in this breast cancer 
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Recent approvals of the Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) allow the treatment of special subcategories of TNBC with 
Poly(ADP-Ribose)-Polymerase (PARP) inhibitors e.g. olaparib for patients with BReast 
CAncer (BRCA) mutated, metastatic TNBC and immune checkpoint inhibitors e.g. 
atezolizumab for Programmed Cell Death Ligand 1 (PD-L1) positive, metastatic TNBC 
(Heimes and Schmidt, 2019; Le and Gelmon, 2018).  
Nonetheless, this subtype has the worst prognosis of all breast cancer types, and 
approximately 11% of breast cancer patients suffer of TNBC (American-Cancer-
Society, 2019). Therefore, the medical need for new therapeutic options is huge. 
1.2 CHALLENGES IN BREAST CANCER TREATMENT 
As mentioned above depending on the subtype of breast cancer there are several 
options for treatment. Nonetheless, many tumors are initially hard to treat or recur. 
Thereby, the development of resistance to therapies and the formation of metastases 
belong to the major obstacles in fighting breast cancer (Weigelt et al., 2005). 
1.2.1 DEVELOPMENT OF CHEMORESISTANCE  
Regarding chemoresistance one can discriminate between de novo and acquired 
resistance. Whereas de novo resistant tumors are per se refractory to the applied 
treatment, acquired resistance appears after initial response to therapies. The latter 
has two possible reasons: the existence of so-called cancer stem cells (CSCs) or clonal 
evolution (Li et al., 2008; Navin, 2014; Vogelstein et al., 1988). 
1.2.1.1 CANCER STEM CELL MODEL 
The cancer stem cell model is based on the assumption that solid tumors are 
heterogenous tissues consisting of different tumor cells like cancer stem cells (CSCs), 
fast proliferating progenitors and differentiated cancer cells. (Lawson et al., 2015; 
Meacham and Morrison, 2013).  
1. INTRODUCTION 
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CSCs are capable to self-renew indefinitely, give rise to a multitude of different cell 
clones and are per se refractory to chemotherapy. One reason is that CSCs are less 
proliferative compared to differentiated cancer cells and are therefore less harmed by 
chemo- and radiotherapy mainly targeting fast dividing cells, (Bao et al., 2006; 
Visvader and Lindeman, 2008). Furthermore, it was previously shown that CSCs 
express high levels of efflux pumps like ABC-transporters e.g., MDR1, BCRP1. These 
P-glycoproteins protect CSCs of cytotoxic agents by removing them from the 
intracellular space (Schatton et al., 2008). Therefore, these CSCs are able to survive 
cancer therapy and give rise to novel tumors (Bai et al., 2018; Carnero et al., 2016). 
1.2.1.2 CLONAL EVOLUTION MODEL 
The clonal evolution is based on the theorem “survival of the fittest”. As 
chemotherapies represent a huge selection pressure on tumors, cancer cells are forced 
to adapt to these cytotoxic agents (Kim et al., 2018a; Navin, 2014). Here, one possible 
escape mechanism is the augmentation of somatic mutations which can be induced by 
several chemotherapies (Wang et al., 2014). This causes increased expression of efflux 
pumps like ABC-transporters e.g., MDR1, BCRP1, which leads to reduced drug 
concentrations in the cancer cells. Moreover, elevated expression of oncogenes like 
growth factors e.g., EGFR induce cell proliferation, differentiation and thus cell survival. 
Also, genomic alterations in DNA repair mechanisms, apoptosis as well as autophagy 
belong to chemoresistance mechanisms (Wein and Loi, 2017; Zheng, 2017). Cancer 
cells that are able to adapt to cytotoxic agents by the above-mentioned mechanisms 
will survive chemotherapy and give rise to novel chemoresistant tumors. 
1.2.2 FORMATION OF METASTASES 
Even though emerging novel treatment options for breast cancer have improved 
patient outcome, metastatic breast cancer is still an incurable disease (American-
Cancer-Society, 2019; Scully et al., 2012) as one of the leading causes of breast cancer 
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Especially, TNBC patients have a high risk to develop a metastatic disease with the 
highest metastatic burden in lung, liver, bone and brain (Eckhardt et al., 2012; 
Valastyan and Weinberg, 2011). The 5-year survival rate of patients with metastatic 
breast cancer is only 20% (Gennari et al., 2005). One reason therefore is the lack of 
therapeutic options. In contrast to early breast cancer where surgery is a major 
component of the therapy this is hardly possible in a metastatic disease situation 
(Harbeck and Gnant, 2017). Moreover, breast cancer is usually diagnosed for the first 
time in a non-metastatic stage. Hence, metastatic breast cancer patients often received 
at least one prior treatment. As the formation of metastases is thought to occur as an 
early dissemination step in cancer development, these cell clones giving rise to 
metastases survived at least one prior cancer treatment and are therefore resistant 
(Lambert et al., 2017). Moreover, cell clones that are able to disseminate from primary 
tumors and colonize in different tissues evolved several clonal evolution steps. This 
results in more robust as well as proliferative phenotypes compared to the primary 
tumor and finally to decreased response to chemotherapy (McGranahan and Swanton, 
2017). Due to these reasons the unmet medical need is very high. 
1.3 AIM OF THE THESIS 
In this thesis, these two major challenges in breast cancer therapy, i.e., development 
of chemoresistance and formation of metastases, were addressed.  
Concerning the development of chemoresistance our aim was to investigate whether 
this process is directed and therefore follows a certain, designated pattern. If the clonal 
evolution leading to resistance alters the protein expression in breast cancer cells 
always in the same way, this process might be manageable or even avoidable by 
targeting the key drivers therapeutically. To investigate this phenomenon in an in vitro 
setting, a so-called “molecular evolution assay” (MEA) was developed in our laboratory. 
Here, breast cancer cells are treated sequentially with recovering periods in between 
mimicking several cycles of chemotherapy in a clinical setting. A subsequent proteomic 
analysis was intended to reveal the alterations of the proteome during chemotherapy 
compared to the parental cell line.  
1. INTRODUCTION 
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As the formation of metastases is another huge challenge in the treatment of breast 
cancer, the investigation of cancer cell migration was the aim in the second part of the 
thesis. As it was previously shown that the G protein-coupled receptor kinase GRK5 
regulates cell migration in prostate cancer cells, its role in breast cancer should be 
investigated in this study. Therefore, the expression of GRK5 in different breast cancer 
cell lines as well as the influence of GRK5 knock-down on cancer cell migration and 
invasion were to be examined. Moreover, a comprehensive proteomics approach was 
intended to reveal signaling pathways regulated by GRK5. To evaluate the clinical 
relevance of GRK5 the impact of this kinase on distant-metastasis free survival in TNBC 
patients was to be examined using the Kaplan-Meier-Plotter. Finally, the therapeutic 
implication of GRK5 should be assessed by treating breast cancer cells with the multi-
kinase inhibitor sunitinib, which was previously shown to inhibit GRK5 amongst others. 
To sum up this thesis addresses two major obstacles in the treatment of breast cancer 
thus increasing the knowledge about development of chemoresistance and 
metastases. This may give rise to research in new medical entities for breast cancer 
therapy. 
2. PROTEOMICS ANALYSIS OF CHEMORESISTANCE DEVELOPMENT 
16 
DISSERTATION ANN-KATRIN SOMMER 
2. PROTEOMICS ANALYSIS OF CHEMORESISTANCE 
DEVELOPMENT 
This chapter was adapted from the original publication, which was finally published as 
Sommer et al., International Journal of Molecular Medicine, 2018; 42, 1987-1997. 
Sections may have been moved for consistency.  
(Sommer et al., 2018) 
 
A proteomic analysis of chemoresistance development via sequential 
treatment with doxorubicin reveals novel players in MCF-7 breast cancer 
cells 
Ann-Katrin Sommer1, Adam Hermawan1, Bojan Ljepoja1, Thomas Fröhlich2, Georg J. 
Arnold2, Ernst Wagner1, and Andreas Roidl1   
1 Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-
Universität, München, D-81377 Munich, Germany 
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2.1 ABSTRACT 
Breast cancer exhibits the highest incidence of all cancer types and is the 2nd leading 
cause of cancer mortality in women. Up to 82% of breast cancer patients receive a 
chemotherapy-containing treatment regimen. However, numerous breast tumors recur 
within ten years following an initial response and are frequently resistant to previous 
therapeutic agents. Thus, to analyze the crucial factors, and whether the development 
of resistance in tumor cells follows certain patterns, is of great importance. In the 
present study, the clinical treatment schedule of the frequently used chemotherapeutic 
drug doxorubicin was applied in an in vitro model, the Molecular Evolution Assay 
(MEA), leading to resistance formation. By investigating the alterations in protein 
expression in MCF-7 breast cancer cells with three biological replicates, it was observed 
that the development of resistance to doxorubicin is a multi-directed process. The 
number and composition of the differentially expressed proteins varied, in addition to 
the pathways involved in chemoresistance, leading to only a small number of proteins 
and pathways being commonly regulated in all the MEAs. The proteins 60S ribosomal 
export protein NMD3 and 4F2 cell-surface antigen heavy chain (SLC3A2) were 
identified to be the most promising differentially expressed targets; the gene ontology 
term ‘apoptotic signaling pathway’ was reduced and ‘cell redox homeostasis’ was 
upregulated. Based on the present findings in vitro, it may be hypothesized that the 
development of resistance in patients is an even more complex process, emphasizing 
the need for further investigations of resistance development in the clinic to eventually 
improve patient outcomes. 
2.2 INTRODUCTION 
According to the American Cancer Society and the International Agency for Research 
on Cancer, breast cancer has the highest incidence of all cancers in women worldwide 
(American Cancer Society, 2018; Globocan, 2012). Furthermore, breast cancer is the 
second-leading cause of cancer deaths in the United States, where, 38% to 82% of 
breast cancer patients, depending on the stage, receive chemotherapy in adjuvant and 
neoadjuvant treatment regimen (Miller et al., 2016).  
2. PROTEOMICS ANALYSIS OF CHEMORESISTANCE DEVELOPMENT 
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One of the most frequently used chemotherapeutics in breast cancer therapy is 
doxorubicin (DXR). This drug belongs to the anthracycline antibiotic family and was 
isolated from the Streptomyces peucetius (Arcamone et al., 1969). It acts by binding 
topoisomerase II (Tewey et al., 1984), via DNA intercalation (Chen et al., 2012) and 
by generating free radicals (Mizutani et al., 2005) resulting in DNA damage 
(Benchekroun et al., 1993; Gewirtz, 1999; Hilmer et al., 2004; Minotti et al., 2004; 
Tacar et al., 2013). A major obstacle in the treatment of breast cancer is the recurrence 
of the tumor. According to the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) 39.4% of breast tumors previously treated with anthracyclines recur within 
ten years (Early Breast Cancer Trialists' Collaborative et al., 2012). A majority of 
relapses are resistant to the previous chemotherapeutic drugs resulting in a poor 
prognosis for breast cancer patients. In general, there are two hypotheses explaining 
the development of chemoresistance: the cancer stem cell (CSC) model and the clonal 
evolution model (Cairns, 1975; Greaves and Maley, 2012; Kopp et al., 2014; Meacham 
and Morrison, 2013; Nowell, 1976; Shackleton et al., 2009). The CSC model is based 
on the hypothesis that solid tumor cells are hierarchically organized with CSC at the 
apex, followed by fast proliferating progenitors and finally differentiated cancer cells. 
CSCs are capable of indefinite self-renewal, give rise to aberrant differentiated cells 
and are intrinsically resistant to chemotherapy (Meacham and Morrison, 2013). The 
clonal evolution model, on the other hand, states that tumor cells are stochastically 
organized and that tumor progression is driven by the fittest clone and not by CSC 
(Greaves and Maley, 2012). Since genomic instability is one hallmark of cancer 
(Hanahan and Weinberg, 2011), mutations in the tumor cells occur spontaneously. A 
subsequent selection pressure or a biological advantage leads to the propagation of 
certain cell clones (Greaves and Maley, 2012). One example of a strong selection 
pressures are chemotherapeutic drugs, including DXR which kill the majority of cancer 
cells, although certain resistant clones survive, giving rise to a new tumor cell 
population that is insensitive to the drug used previously (Bedard et al., 2013; Turner 
and Reis-Filho, 2012).  
  
2. PROTEOMICS ANALYSIS OF CHEMORESISTANCE DEVELOPMENT 
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Previous studies demonstrated that DXR resistant cancer cells exhibit activated DNA 
damage repair mechanisms (Bankusli et al., 1989), alterations in topoisomerase II 
expression (de Jong et al., 1990), overexpression of drug metabolizing enzymes 
(Gehrmann et al., 2004; Wang et al., 2015), mutations in cellular tumor antigen p53 
(Aas et al., 1996) and, particularly, enhanced drug efflux mediated by transporters 
belonging to the ATP-binding cassette superfamily (Gottesman, 2002; Hermawan et 
al., 2016). However, all of the in vitro studies dealing with DXR resistance have 
analyzed resistant cells which were permanently maintained in DXR-containing media. 
In the clinical setting however, chemotherapy with DXR is usually applied in four cycles 
of 60 mg/m2 every third week in combination with cyclophosphamide (Early Breast 
Cancer Trialists' Collaborative et al., 2012). Recovery phases up to two weeks in 
between are an important part of the therapy to allow the patient to cope with the 
toxic drugs.  
Therefore, the aim of the present study was to investigate the development of 
resistance by treating breast cancer cells for five rounds with DXR, and including 
treatment-free periods in between, thus mimicking the clinical therapy regimen of 
patients. This assay was termed the Molecular Evolution Assay (MEA), as it was 
possible to observe alterations in the protein expression upon a selection pressure (in 
this case, DXR) over time. This assay may reflect the development of acquired 
resistance in a more realistic way compared with constant high-dose drug treatments. 
Three independent MEAs (A, B and C) were performed in the breast cancer cell line 
MCF-7 to address the question of whether resistance formation follows similar patterns 
upon the same selection pressure, and to identify its crucial factors. Thus, the present 
study analyzed different biological replicates under the same conditions. In order to 
investigate the alterations in protein expression during resistance formation, a 
proteomics approach using liquid chromatography-mass spectrometry (LC-MS) was 
performed. This technique revealed differentially expressed proteins by comparing 
untreated cells with cells treated three and five times, thus elucidating important 
mechanisms of resistance formation. 
2. PROTEOMICS ANALYSIS OF CHEMORESISTANCE DEVELOPMENT 
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2.3 RESULTS 
2.3.1 MEA MIMICS RESISTANCE DEVELOPMENT 
Chemoresistance remains one of the primary obstacles to treating cancer. Thus, an in 
vitro model that mimics sequential treatment in the clinic was established to investigate 
the development of resistance to DXR. In the present study, the breast cancer cell line 
MCF-7 was treated with 50 nM doxorubicin for five rounds. Generally, each round 
consisted of a treatment phase (72 h; 50 nM DXR) and a recovery phase. The next 
round was initiated when cells had recovered, indicated by attaining 80% confluency. 
At the beginning of the MEA (R0) and subsequent to the recovery phases of R3 and 
R5, cells were seeded for cell viability assays and proteomic analyses. A total of three 
independent biological replicates were performed to investigate the process of 
resistance formation. These replicates were termed MEA A, B and C (Fig. 3A). Different 
passage numbers of the parental cells (R0) were chosen (passage 5 for MEA A, passage 
7 for MEA B and passage 8 for MEA C) to compensate for possible clonal effects or cell 
culture artefacts. R0, R3 and R5 of the three different MEAs (A, B and C) were further 
analyzed. Every proteomics sample was analyzed three times and are measurement 
replicates in the following sections. 
2.3.2 DEVELOPMENT OF RESISTANCE UPON DOXORUBICIN TREATMENT DIFFERS IN 
MEA A, B AND C 
To examine the sensitivity of the cells to 1 µM DXR, the untreated MCF-7 cells (R0), 
and R3 and R5 of the MEAs A, B and C, were analyzed by a cell viability assay. It was 
observed that resistance to DXR developed differently in each MEA (Fig. 3B). In the 
MEA A R3, a 1.3-fold decreased sensitivity to DXR was noted, whereas R5 displayed 
almost the same sensitivity to DXR as the untreated MCF-7 cells. R3 of MEA B was also 
1.3-fold more resistant to treatment with DXR compared with the parental cells (R0), 
and the resistance was maintained in R5.  
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MEA C, on the other hand, exhibited no resistance increase in R3, although R5 
exhibited the highest increase in resistance to DXR compared with all other MEAs. 
These data indicated that the development of resistance to DXR in the different MEAs 
was neither constantly increasing nor occurring in a consistent manner. 
2.3.3 PROTEOMIC ANALYSIS OF THE TREATMENT ROUNDS REVEALS NO INCREASE IN 
DIFFERENTIAL PROTEIN EXPRESSION IN LATER ROUNDS  
Alterations in protein expression during resistance formation were analyzed using a 
label-free proteomics approach. Herein, ~3,000 proteins were identified in each 
measurement.  
To visualize the expression alterations between R0, R3 and R5 of MEA A, B and C, a 
scatter blot analysis was performed (Fig. 3C). In the left scatter blots, depicting the 
parental MCF-7 cells at different passage numbers, the spots are very close to the 
bisecting line of an angle, indicating that the protein expression of the untreated cells 
in MEA A, B and C hardly differed. The Pearson correlation value of 0.94 emphasizes 
these results. The scatter blots in the middle panel illustrate that the spots of R3A 
compared with R3B, and R3A compared with R3C, diverge more from the bisector. 
Likewise, the Pearson correlation indices decreased. Thus, the protein expression in 
R3 of MEA A, B and C differed more amongst each other compared with that of the 
untreated cells (R0). The right panel displays the comparison of the different R5s and 
illustrates that the perturbation of protein expression in general was not further 
increased by additional treatments with DXR. Thus, it was identified that the parental 
cells (R0) were similar in protein expression and that a considerable perturbation was 
induced by three treatment rounds with DXR. A total of five treatment rounds with 
DXR, however, did not lead to a further increase in the difference in protein expression. 
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Figure 3. Introduction of the MEA. (A) Schematic representation of the MEA. MCF-7 cells were treated 
by Dr. Adam Hermawan in five rounds (R1-R5) with 50 nM DXR for 72 h. In between the treatment 
rounds, the cells were allowed to recover until they reached a confluence of 80%. Three independent 
biological replicates were performed with cells at passage number 5, 7 and 8 (MEA A, B, C). R0, R3 and 
R5 were used for further analysis. Proteomics analysis were performed by Dr. Thomas Fröhlich and Dr. 
Georg J. Arnold, Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU (B) Analysis 
of resistance formation in MCF-7 cells. To evaluate the resistance formation to DXR, the MCF-7 cells of 
R0, R3 and R5 in MEA A, MEA B and MEA C were seeded in triplicate, treated with 1 µM doxorubicin for 
72 h and subsequently analyzed by applying a CellTiter-Glo Luminescent cell viability assay. Results are 
presented as the mean + standard deviation. A two-tailed paired Student's t-test was performed to 
evaluate significance. *P<0.05.  
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(C) Multiscatter analysis. To evaluate the similarity of the different rounds, a multiscatter analysis was 
performed. The median of three measurement replicates was calculated and R0, R3 and R5 of MEA A, 
B and C were compared with each other. A Pearson correlation index close to 1 indicates high similarity. 
MEA, Molecular Evolution Assay; R, round; DXR, doxorubicin. 
2.3.4 GSEA REVEALS SIGNALING PATHWAYS INVOLVED IN THE DEVELOPMENT OF 
RESISTANCE TO DXR  
To investigate the alterations in signaling pathways involved in the development of 
chemoresistance in the different MEAs, a GSEA (Mootha et al., 2003; Subramanian et 
al., 2005) was performed. The global ES histogram in Fig. 4A gives an overview of up- 
and downregulated proteins and illustrates that in R3 the majority of proteins were 
downregulated. This effect was even more marked in R5 compared with R0. For a 
more detailed analysis, the MEAs were examined separately. The differences in 
enriched gene sets are visible in the global ES histograms (Supplementary Figure S1). 
Furthermore, the results were screened for GO terms and pathways known to be 
relevant for resistance formation (Shibue and Weinberg, 2017). The normalized ES of 
the selected pathways exhibit alterations occurring between R0, R3 and R5 
(Supplementary Figure S2). Proteins assigned to the GO pathway ‘apoptotic signaling 
pathway’ were reduced following three and five treatment cycles with DXR in all MEAs 
(Fig.4B). On the other hand, ‘cell redox homeostasis’ was generally upregulated in the 
DXR-treatment rounds (R3 and R5) and all MEA replicates (Fig. 4C). All other analyzed 
pathways, including ‘locomotion’, ‘cell cycle’, ‘autophagy’, ‘cell motility’, ‘cell division’, 
‘detoxification’, ‘response to toxic substance’ and ‘glutathione metabolic process’, 
differed between MEA A, B and C (Supplementary Figure S2). Therefore, all cells in 
this setting escaped the chemotherapeutic selection pressure of DXR, primarily by 
reducing the expression of proteins belonging to the GO pathway ‘apoptotic signaling 
pathway’ and increasing the expression of the members of ‘cell redox homeostasis’. 
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Figure 4. GSEA. GSEA was performed using gsea2-2.2.3 from the Broad Institute. (A) Global 
enrichment score histogram. The global enrichment score histograms are depicted to illustrate an 
overview of the amount of upregulated and downregulated gene sets in all the MEAs, comparing R3 
and R5 with R0. (B) Apoptotic signaling pathway. The normalized enrichment score was used to facilitate 
the comparison of different MEAs. (C) Cell redox homeostasis. The normalized enrichment score was 
used to facilitate the comparison of different MEAs. GSEA, gene set enrichment analysis; R, round; MEA, 
Molecular Evolution Assay. 
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2.3.5 COMPARING THE DIFFERENT MEAS REVEALS 111 PROTEINS WITH DECREASED 
AND 42 PROTEINS WITH INCREASED EXPRESSION IN ALL CONDITIONS  
Subsequently, the three biological replicates (MEA A, B and C) were analyzed 
separately for up- and downregulated proteins. A total of ~1,000 proteins exhibited 
decreased or increased expression between R3 and R0 or R5 and R0 in each of the 
MEAs (Fig. 5). However, the amount of differentially expressed proteins was not 
consistent among the individual MEAs. To identify proteins which were commonly up- 
or downregulated in all MEAs, a Venn analysis was performed. Fig. 5A illustrates the 
number of proteins with reduced expression upon treatment with DXR. Following three 
treatment cycles with DXR, 360 proteins out of all the downregulated proteins were 
identical in all three MEAs (R3 vs. R0). Furthermore, 317 proteins were commonly 
downregulated in all MEAs following five treatment cycles with DXR (R5 vs. R0). 
Subsequently, these 360 proteins, which were downregulated in all MEAs following 
three treatment rounds with DXR, and the 317 proteins that were reduced following 
five treatment rounds, were compared in a further Venn diagram to determine the 
proteins exhibiting decreased expression in R3 and R5 compared with R0. A total of 
111 proteins were commonly downregulated in all MEAs upon three and five treatment 
rounds with DXR. The same analysis was performed for proteins with increased 
expression (Fig. 5B). A total of 160 proteins were commonly upregulated in all MEAs, 
comparing R3 with R0. The analysis of R5 compared with R0 revealed 162 proteins 
with increased expression in all MEAs. The obtained proteins of R3 compared with R0 
and R5 compared with R0 were further compared, and 42 proteins were detected as 
commonly upregulated. These up- and downregulated proteins are presented in tables 
in the Supplements. Taken together, the analysis of the protein abundance of the 
different MEAs revealed only a few commonly regulated proteins. 
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Figure 5. Comparison of MEA A, B and C. In order to compare MEA A, B and C, proteins that were 
identified twice in at least one group were analyzed. Missing values were replaced from a normal 
distribution (width, 0.3; down shift, 1.8) and a Student's t-test was performed to evaluate alterations in 
protein expression upon treatment with doxorubicin. Subsequently, proteins were sorted according to 
their t-test difference (<0, downregulated; >0, upregulated). (A) Venn diagram of downregulated 
proteins. To investigate the number of commonly regulated proteins between MEA A, B and C, a Venn 
analysis was performed. The downregulated proteins of R3 (left) and R5 (right) compared with R0 were 
analyzed. Proteins exhibiting decreased expression in R3 and R5 across all MEAs were again compared 
to elucidate which proteins were downregulated between R0 and R3 and between R0 and R5. (B) Venn 
diagram of upregulated proteins. The Venn diagrams illustrate the amount of commonly upregulated 
proteins in MEA A, B and C. Left, upregulated proteins in R3 compared with R0. Right, upregulated 
proteins in R5 compared with R0. Proteins with increased expression in all MEAs were compared to 
determine the number of continuously upregulated proteins. MEA, Molecular Evolution Assay; R, round. 
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2.3.6 ANALYSIS OF DIFFERENTIALLY EXPRESSED PROTEINS REVEALS THE 20 PROTEINS 
WITH THE HIGHEST OVERALL EXPRESSION ALTERATION  
Subsequently, the three MEAs were analyzed separately for differentially expressed 
proteins, with a threshold of a 1.5-fold change. This led numbers of downregulated 
proteins between R3 and R0 of 946 in MEA A, 212 in MEA B and 233 in MEA C. A 
smaller number of proteins were upregulated: 318 in MEA A, 307 in MEA B and 146 in 
MEA C. Regarding alterations in protein expression comparing R5 to R0, it was 
observed that 851 proteins in MEA A, 960 in MEA B and 435 in MEA C were differentially 
expressed. Only 4-7% of all identified and differentially expressed proteins were 
commonly regulated in all MEAs (Fig. 6A hatched area). 
In Fig. 6B, the 20 proteins with the highest overall abundance alterations are depicted, 
displaying their relative expression and the respective P-values.  
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Figure 6. Differentially expressed proteins. For a comparison of MEA A, B and C only proteins that were 
identified twice in at least one group were considered. Missing values were imputated (width, 0.3; down 
shift, 1.8). In order to determine the alterations in protein expression during resistance formation, a 
Student's t-test was performed and R3 vs. R0 and R5 vs. R0 were compared. Only proteins exhibiting a 
Student's t-test difference of at least |0.6| (1.5-fold) were further examined. The proteins with 
decreased expression levels are presented as negative values, and vice versa. (A) Number of 
differentially expressed proteins. The differentially expressed proteins of R3 (left) and R5 (right) 
compared with R0 were analyzed. The hatched area represents the commonly regulated proteins.  
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(B) Proteins with the highest abundance alterations. The depicted tables illustrate the proteins with the 
highest abundance alterations across all MEAs. In the upper table the 10 proteins with the largest overall 
increase in expression are presented. The lower table displays the 10 proteins with the greatest 
reduction in expression upon treatment with doxorubicin. A two-tailed student's t-test with a false 
discovery rate of 0.05 was used to compare R3 with R0 and R5 with R0. P<0.05 was considered to 
indicate a statistically significant difference. MEA, Molecular Evolution Assay; R, round; RE, relative 
expression. 
2.3.7 COMMONLY REGULATED PROTEINS ARE LIKELY TO BE ASSOCIATED WITH 
CHEMORESISTANCE.  
In order to identify the most promising targets in the development of chemoresistance, 
treated samples (R3 and R5) were compared with untreated samples (R0) across all 
three MEAs. The proteins which were present in all MEAs (A, B and C) were further 
analyzed, according to their differential expression. Finally, 15 proteins with the highest 
overall expression alterations are presented in a table in the Supplements. The majority 
of these proteins are known to be involved in crucial mechanisms and pathways, 
including tumorigenesis, the cell cycle and apoptosis. A total of two representative 
proteins are presented in Fig. 7. 60S ribosomal export protein NMD3 (NMD3) is a 
representative example of proteins which were downregulated upon treatment with 
DXR in every MEA and exhibited a decrease in protein expression. On the other hand, 
4F2 cell-surface antigen heavy chain (SLC3A2) was upregulated 12.7-fold on average, 
and represents an example of increasing proteins expression levels (Fig. 7A). The 
detailed alteration in expression of these targets in the individual MEAs and rounds is 
displayed in Fig. 7B. The individual expression levels overall followed a similar trend 
throughout the MEAs: Reduced expression following treatment with DXR in the case 
of NMD3, and an increase in SLC3A2. This indicated the importance of these proteins 
in resistance development. To further evaluate the impact of these proteins on cancer 
progression, the RFS of a cohort of patients with breast cancer (luminal A tumors) was 
investigated in silico using a Kaplan-Meier analysis provided by Kaplan-Meier Plotter 
(Gyorffy et al., 2010). Breast tumors with low NMD3 expression levels recurred earlier 
[hazard ratio (HR) =0.7] compared with tumors exhibiting high NMD3 expression. In 
line with the present proteomic analysis, high expression levels of SLC3A2 led to 
shorter RFS periods in comparison with tumors with low SLC3A2 expression (HR =1.4) 
(Fig. 7C). 
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Figure 7. Potential common drivers of chemoresistance. Treated cells (R3 and R5) were compared with 
untreated cells (R0) to identify proteins that were commonly regulated during resistance formation 
across all MEAs. NMD3 and SLC3A2 are presented as representative examples. (A) Global comparison 
of treated and untreated cells. All values are depicted as relative expression values normalized to 
untreated cells, and are presented as the mean + standard deviation of all MEAs. (B) Detailed analysis 
of each MEA. The LFQ values of each round are depicted here as the mean + standard deviation of the 
measurement replicates. (C) Kaplan-Meier plots. The relapse-free survival of luminal A breast cancer 
patients was analyzed using the GSE21653 dataset. MEA, Molecular Evolution Assay; R, round; NMD3, 
60S ribosomal export protein NMD3; SLC3A2, 4F2 cell-surface antigen heavy chain; LFQ, label free 
quantification. 
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2.4 DISCUSSION 
Drug resistance remains one of the principal obstacles in the treatment of cancer and 
frequently correlates with tumor relapse, in addition to poor patient outcomes. In the 
present study, the development of chemoresistance was investigated using a 
proteomics approach, to acquire a comprehensive analysis of the fundamental factors, 
patterns and mechanisms.  
To generate chemoresistance, other studies have maintained cells in DXR-containing 
medium, whereas in the present study, to the best of our knowledge for the first time, 
cells were treated in rounds with treatment-free periods and were subsequently 
analyzed with proteomics. Persistent treatment with DXR leads to a continuous up- or 
downregulation of proteins compensating for the permanent toxic stress, similar to 
multiple drug resistance mechanisms, including the upregulation of 5’-adenosine 
triphosphate-binding cassette transporters (Aas et al., 1996; Bankusli et al., 1989; de 
Jong et al., 1990; Gehrmann et al., 2004; Gottesman, 2002; Hermawan et al., 2016; 
Wang et al., 2015). In the present assay, the temporary absence of the selection 
pressure caused further perturbations in protein expression. This increased the 
complexity of the resistance model. The removal of DXR leads to regrowth of surviving 
cells in which the fittest clones with the highest proliferation rate have the highest 
impact on the composition of the recurrent tumor cell population. Therefore, it was 
hypothesized that the MEA was more reflective of the therapeutic regimen in the clinic. 
Analyzing resistance formation by MEA may thus lead to novel insights. 
The development of chemoresistance in tumors may generally be explained by two 
hypotheses: The CSC model and the clonal evolution model (Cairns, 1975; Greaves 
and Maley, 2012; Kopp et al., 2014; Meacham and Morrison, 2013; Nowell, 1976; 
Shackleton et al., 2009). Choi et al (Choi et al., 2017) reported that only 1.2% of wild 
type MCF-7 cells exhibit a CSC-like phenotype. If only these CSCs had survived the 
treatment, a more homogenous protein pattern, in addition to an increase in stem cell 
markers, may have been detected in the present study.  
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Therefore, it may be hypothesized that CSCs have only a minor impact on the 
development of chemoresistance in the present setting, and the clonal evolution model 
may therefore be favored for the present in vitro resistance assay. There are numerous 
pathways involved in drug resistance (Aas et al., 1996; Bankusli et al., 1989; de Jong 
et al., 1990; Gehrmann et al., 2004; Gottesman, 2002; Wang et al., 2015) in which 
proteins were not observed to be altered in the present study. A possible reason may 
be conditions of this assay, for example with recovery phases and sequential 
treatment. Another reason may be the performed proteomic analysis. The analysis of 
differentially expressed proteins with the present method has a number of advantages 
compared with frequently used genomics methods. However, it is not possible to 
perform a comprehensive analysis due to limitations in detecting the entirety of human 
proteins. Furthermore, the applied proteomic analysis is not able to detect alterations 
in mRNA expression levels, which a number of publications have investigated (Aas et 
al., 1996; Gottesman, 2002). Furthermore, it has been reported that there is only a 
very weak correlation between mRNA expression levels and protein expression (Pertea, 
2012). However, protein expression is responsible for the manifestation of biological 
phenotypes and, therefore, a proteomics approach may be the superior analysis for 
the evaluation of resistance formation. By applying the label-free LC-MS technique in 
the present study, 3,000 of the 30,057 human proteins (Kim et al., 2014) were 
identified, a notable improvement compared with previous studies (Holm et al., 2018; 
Koplev et al., 2018; Wang et al., 2015). Also, stringent cut-off criteria were chosen to 
minimize the detection of false positive results.  
For an unbiased analysis, a GSEA was utilized. Common resistance mechanisms, 
including ‘apoptotic signaling pathway’ and ‘cell redox homeostasis’ were 
demonstrated to be altered. A reduction in apoptosis is a common mechanism through 
which to escape cell death, and has been reported in previous studies (Marin et al., 
2016; Pfeffer and Singh, 2018). Particularly in the context of treatment with DXR, the 
increased expression of proteins regulating cell redox homeostasis is plausible. This 
pathway analysis further demonstrated that the development of resistance to DXR 
differed in each MEA.  
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By comparing treated (R3 and R5) with untreated cells (R0) of all MEAs, NMD3 and 
SLC3A2 were identified to be representative examples of downregulated or 
upregulated proteins, respectively. SLC3A2 is associated with cell survival, migration 
and tumor growth in renal cancer, and may thus be a promising resistance marker in 
breast cancer (Poettler et al., 2013; Prager et al., 2009). Additionally, NMD3 has a 
marked impact on RNA biosynthesis, particularly ribosomal RNA synthesis, and may 
therefore influence tumorigenesis in general (Bai et al., 2013); however, a direct role 
for this protein in chemoresistance remains to be elucidated.  
The results of the present study demonstrated through the commonly up- or 
downregulated targets that the development of chemoresistance differed in each MEA. 
Thus, only a few general drivers of resistance formation were identified (4-7% of the 
identified proteins) and >90 % of the differentially expressed proteins were altered 
only in one of the assays. This phenomenon may be caused, on the one hand, by 
slightly heterogeneous initial protein expression due to pre-existing genomic instability 
and, on the other hand, by the treatment with DXR, which had the highest impact on 
the perturbation of differentially expressed proteins in MEA A, B and C. It was not 
possible to detect a dominant pattern of differential protein expression which was 
reproducibly present in all replicates. The assay conditions and analyses also did not 
allow for the drawing of conclusions as to whether resistance formation is a stochastic 
or, at least, a multi-directed process, as an increased number of replicates may identify 
patterns in resistance formation. Furthermore, it was observed that the sensitivity to 
DXR varied in each MEA during the five treatment rounds. Chemoresistance is defined 
as the insensitivity of tumor cells to chemotherapeutic drugs, leading to tumor 
progression during chemotherapy (Schwab, 2011). However, the underlying 
mechanisms are different. One such mechanism is intrinsic drug resistance; this means 
that tumor cells are resistant to the applied drug from the beginning of treatment. The 
other mechanism is acquired resistance, wherein tumor cells develop resistance to the 
applied drug following an initial response (Sommer et al., 2016). In the present study, 
it was observed that in MEA A, for example, five times-treated cells exhibited the same 
sensitivity to DXR as untreated cells. This indicated that five treatment rounds with 
DXR did not further increase resistance compared with three times-treated cells, and 
also that resistance may not be a persistent condition.  
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Furthermore, it was demonstrated that five treatment rounds altered protein 
expression while not necessarily increasing resistance to the applied drug. This 
observed effect may be due to clonal selection, which favors faster growing cell clones 
that then represent the majority of cells in the recovery phase. Thus, the present assay 
did not select for the most resistant clones; rather, for those that survived the 
treatment and were subsequently able to repopulate. This resembles the situation in 
the clinic more accurately than maintaining a constant selection pressure.  
Additionally, the diversity in the development of resistance may be due to the 
heterogeneity of tumor cells. According to The Cancer Genome Atlas and the 
International Cancer Genome Consortium, estrogen receptor positive (ER+) breast 
cancer exhibits the greatest diversity concerning gene expression, mutations, 
alterations in copy numbers and patient outcomes (Cancer Genome Atlas, 2012; Nik-
Zainal et al., 2016; Parker et al., 2009). Thus, it may be hypothesized that the response 
to chemotherapy may differ in each patient. This may lead to varying selection of 
resistant clones, which give rise to metastases and recurrent tumors. It was previously 
reported that disseminating breast cancer cells exhibit a different gene expression 
pattern and an increased resistance to chemotherapeutics compared with the primary 
tumor (Goswami et al., 2009; Goswami et al., 2004; Patsialou et al., 2012; Wang et 
al., 2003; Wyckoff et al., 2000; Yates et al., 2017). Furthermore, Folgueira et al (Koike 
Folgueira et al., 2009) demonstrated, by comparing ER+ breast tumor samples pre- 
and post-treatment with DXR and cyclophosphamide, that 389 genes were 
differentially expressed.  
Another general reason for the heterogeneity of tumors is genomic instability, a 
hallmark of cancer (Hanahan and Weinberg, 2011). Tomasetti et al (Tomasetti et al., 
2017) reported that the majority of mutations leading to tumorigenesis are random 
DNA replication errors, aside from hereditary and environmental mutations. This 
finding indicated that every patient with breast cancer may exhibit a different response 
to therapy, RFS and overall survival. 
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In conclusion, the present in vitro model indicated that the development of 
chemoresistance is a multi-directed or varying process. Due to the genomic instability 
in breast cancer, the response to chemotherapeutics, and thus the development of 
resistance by clonal selection, may be an event that rarely follows certain patterns.  
Transferred to the clinical setting with even more perturbations in resistance formation, 
these results may explain why cancer remains difficult to treat and why the patient 
outcome is hard to predict. This furthers emphasizes the requirement for an individual 
diagnosis of resistance markers, in addition to patient-tailored therapy. 
 
2.5 MATERIALS AND METHODS 
2.5.1 CELL CULTURE 
The breast cancer cell line MCF-7 was obtained from CLS Cell Lines Service GmbH 
(Eppelheim, Germany) and cultured in Dulbecco’s modified Eagle’s medium high 
glucose (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) containing 10% fetal calf 
serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37˚C and 5% CO2. 
For the following experiments, cells were used at passage number 5 (MEA A), 7 (MEA 
B) and 8 (MEA C), respectively. 
2.5.2 MOLECULAR EVOLUTION ASSAY 
The MEA was performed by Dr. Adam Hermawan as described previously (Kopp et al., 
2012). MCF-7 cells were treated with 50 nM DXR (Sigma-Aldrich; Merck KGaA) for 72 
h. Subsequently, the drug was removed and the remaining cells were cultured until 
they reached a confluence of 80%. Finally, the cells were split and 4 days subsequently 
one dish was taken for the next treatment round, one for proteomics analysis and one 
for cell viability measurements. The rounds 0 (R0), 3 (R3) and 5 (R5) were used for 
proteomics analysis. This experiment was performed three times independently. 
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2.5.3 CELL VIABILITY ASSAY 
To assess the resistance formation of R3 and R5 compared with R0, a CellTiter Glo 
Assay (Promega Corporation, Madison, WI, USA) was performed. Untreated cells, three 
times DXR-treated and five times DXR-treated cells were seeded in triplicates (3,000 
cells/well), treated with 1 µM DXR for 72h and were analyzed subsequently using a 
luminometer (Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany), 
according to the manufacturer’s protocol. 
2.5.4 PROTEIN LYSIS 
For protein lysis, cells were seeded at a density of 80%, washed three times with cold 
PBS and subsequently harvested using a protein lysis buffer containing 8 M urea and 
400 mM ammonium bicarbonate. To improve cell lysis, ultrasound was used and 
samples were centrifuged through QIA-shredder devices (Qiagen GmbH, Hilden, 
Germany) at 2,800 x g for 1 min at room temperature. A total of 20 µg protein was 
used for subsequent reduction with 45 mM dithioerythritol (DTE) and for alkylation 
with 0.1 M iodoacetamide, both performed for 30 min at room temperature. Finally, 
samples were trypsinized at 37˚C overnight using 400 ng porcine trypsin. 
2.5.5 LIQUID-CHROMATOGRAPHY MASS SPECTROMETRY  
LC-MS was performed by Dr. Thomas Fröhlich and Dr. Georg J. Arnold, Laboratory for 
Functional Genome Analysis (LAFUGA), Gene Center, LMU. Peptide separation and 
identification was performed on an EASY-nLC 1000 chromatography system (Thermo 
Fisher Scientific, Inc.) coupled to an Orbitrap XL instrument (Thermo Fisher Scientific, 
Inc.). A total of 2.5 µg peptides was diluted in 10 µl 0.1% formic acid and injected on 
a trap column (PepMap100 C18; 75 µm x2 cm; 3 µm particles; Thermo Fisher Scientific, 
Inc.).  
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Chromatography was performed at a flow rate of 200 nl/min at 40˚C (column, PepMap 
RSLC C18; 75 µm x50 cm; 2 µm particles; Thermo Fisher Scientific, Inc.) with a 260-
min linear gradient of 5-25% solvent B (0.1% formic acid; 100% acetonitrile) and a 
subsequent 60-min gradient of 25-50 % solvent B.  
MS spectra were acquired using a top five data dependent collision-induced 
dissociation method. Mass spectra were acquired in parallel mode performing the 
precursor mass scanning in the Orbitrap (60,000 full width at half maximum resolution 
at m/z 400; 300-2,000 m/z), and five data dependent collision-induced dissociation 
tandem MS scans (dynamic exclusion activated) in the LTQ ion trap at a collision 
energy of 35%.  
2.5.6 BIOINFORMATICS 
The mass spectrometry data were processed using MaxQuant 1.5.1.0 (Tyanova et al., 
2015). To analyze the MS data, the Perseus module of the MaxQuant software was 
used (Tyanova et al., 2016). For the following investigations the label free 
quantification value of the identified proteins was used and proteins that were 
identified as potential contaminants or only identified by site were excluded. 
Subsequently, the values were transformed applying the logarithm to base 2. 
For the multiscatter blot, the R0s of each MEA were compared with each other to 
identify the initial perturbation of protein expression at different passage numbers (5, 
7 and 8) of MCF-7 cells. Therefore, two valid values in at least one MEA were required 
and the missing values were replaced from a normal distribution using the imputation 
feature of Perseus (width, 0.3; down-shift, 1.8). Subsequently, the median of each 
MEA was calculated and the R0s of the different MEAs were compared with each other 
applying a Pearson correlation analysis (Perseus module of the MaxQuant software). 
The same analysis was used to compare the different R3s and R5s.  
A gene set enrichment analysis (GSEA) was performed to evaluate alterations in 
signaling pathways. All MEAs were grouped to investigate the overall abundance 
alterations in R3 and R5 compared with R0. Subsequently, each MEA was analyzed 
separately and the measurement replicates were grouped.  
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Only proteins that were identified twice in at least one group were further investigated. 
The missing values were replaced from a normal distribution. The resulting values were 
analyzed with gsea2-2.2.3 from the Broad Institute (Cambridge, MA, USA) (Mootha et 
al., 2003; Subramanian et al., 2005).  
The gene set database gene ontology biological process (GO_BP) (Ashburner et al., 
2000) was used, and as metric for ranking genes the t-test was chosen. The global 
enrichment score (ES) reflects the degree to which a defined set of genes is 
overrepresented at the top or the bottom of the entire ranked gene list, and it 
corresponds to a weighted Kolmogorov-Smirnov-like statistic. 
Subsequently, the MEAs A, B and C were examined separately to evaluate the 
differentially expressed proteins. The three measurement replicates of R0, R3 and R5 
were grouped and two valid values in at least one group were required for further 
investigation. The missing values were replaced applying the aforementioned 
imputation feature of Perseus to allow for statistical evaluation. In the present study, 
a two-tailed and paired Student’s t-test with a false discovery rate of 0.05 was 
performed to compare R0 with R3 and R0 with R5 using the Perseus module of the 
MaxQuant software. To identify up- and downregulated proteins they were sorted 
according to their t-test difference, and values >0 were regarded as increased and <0 
as decreased protein expression. Following this, Venn analysis was performed to 
determine the common regulated proteins in MEA A, B and C. Venny 2.1 was utilized 
(Oliveros, 2007-2015). Finally, the common regulated proteins were compared by Venn 
analysis to identify proteins which were up-or downregulated in R3 and R5 compared 
with R0 in all the MEAs.  
For further analysis, only proteins with an abundance alteration of at least log2-fold 
were considered. The significance of the differential expression was evaluated also, 
and P<0.05 was considered to indicate a statistically significant difference. To identify 
the ten proteins with the highest increases or decreases in protein expression, the 
average of the relative expression values in R3 and R5 of MEA A, B and C was 
calculated and sorted by size. The proteins with the ten lowest and the ten highest 
overall relative expression values were listed in tables in the Supplements. 
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To identify the most important targets in resistance formation, MEA A, B and C were 
analyzed separately and all valid values were used for further evaluation. Those 
proteins that followed the criteria for validity in each MEA were further analyzed.  
The measurement replicates of R0 were grouped (untreated) in addition to the 
measurement replicates of R3 and R5 (treated) and the means were compared with 
each other. The 15 proteins with the highest overall abundance alterations were 
selected. In order to evaluate the clinical relevance of these proteins, the Kaplan-Meier 
Plotter (Gyorffy et al., 2010) was used (release 2018/02/12). The relapse-free survival 
(RFS) in patients with luminal A breast cancer in the dataset GSE21653 was 
investigated. 
2.6 SUPPLEMENTS                
Supplementary figure 1 (S1): Global enrichment score histogram 
A) R3 vs R0 
 
 
B) R5 vs R3 
 
MEA A MEA B MEA C 
MEA C MEA B MEA A 
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C) R5 vs R0 
 
 
The global enrichment score histogram depicts the amount of up- (positive ES values) 
and down-regulated (negative ES values) gene sets.  
  
MEA A MEA B MEA C 
2. PROTEOMICS ANALYSIS OF CHEMORESISTANCE DEVELOPMENT 
41 
DISSERTATION ANN-KATRIN SOMMER 
Supplementary figure 2 (S2): Normalized enrichment scores of resistance 
related GO_BP pathways 
 
Gene set enrichment analysis of differentially expressed proteins. Resistance related 
Gene ontology biological processes (GO_BP) were selected and the normalized 
enrichment score is depicted to compare the different MEAs. 
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Supplementary table 1(ST1): Common down-regulated targets 




















GFRA1 0,20 3,7E-05 0,12 4,5E-04 0,60 4,7E-03 0,11 8,1E-04 0,50 5,4E-02 0,19 9,8E-03 
TAX1BP3 0,15 6,1E-04 0,11 8,7E-04 0,21 1,3E-04 0,31 1,6E-01 0,23 1,7E-01 0,91 2,5E-01 
PRKAR1A 0,19 7,0E-04 0,31 4,5E-03 0,62 2,9E-02 0,17 1,5E-02 0,32 5,1E-03 0,42 2,2E-02 
CNBP 0,25 3,7E-02 0,41 7,8E-02 0,45 3,2E-02 0,77 4,0E-01 0,30 2,8E-02 0,19 6,4E-02 
AGR3 0,31 1,3E-03 0,27 2,4E-03 0,37 1,6E-03 0,13 5,6E-04 0,77 6,9E-01 0,66 5,4E-01 
CA2 0,01 2,5E-05 0,01 7,7E-05 0,93 1,0E-02 0,01 2,7E-06 0,77 3,7E-01 0,77 6,6E-02 
CMBL 0,49 5,6E-02 0,65 1,5E-03 0,47 5,7E-03 0,07 7,4E-05 0,48 6,0E-02 0,43 3,6E-02 
NMD3 0,13 1,3E-04 0,44 1,2E-02 0,72 2,7E-03 0,25 4,7E-04 0,49 6,5E-02 0,57 1,1E-01 
PNPO 0,43 2,1E-02 0,10 9,4E-05 0,77 2,3E-01 0,58 1,7E-01 0,25 6,2E-02 0,59 4,3E-04 
TPD52L2 0,28 1,5E-03 0,23 1,6E-02 0,79 1,1E-02 0,93 3,6E-01 0,39 1,5E-01 0,36 2,6E-01 
CLPB 0,34 4,0E-02 0,37 6,2E-02 0,86 4,7E-01 0,47 3,7E-02 0,57 2,6E-01 0,52 2,0E-01 
PRPF6 0,30 9,6E-03 0,48 4,4E-02 0,62 4,1E-02 0,34 9,3E-04 0,76 3,1E-01 0,65 1,3E-01 
STAU1 0,17 1,7E-05 0,23 7,4E-05 0,98 7,8E-01 0,32 1,0E-04 0,54 3,4E-03 0,93 3,6E-01 
KYNU 0,07 3,6E-05 0,83 3,8E-01 0,54 3,4E-02 0,41 4,9E-03 0,74 2,1E-01 0,63 1,4E-02 
HAT1 0,11 1,4E-05 0,50 5,3E-03 0,90 2,7E-01 0,20 4,3E-05 0,84 6,1E-01 0,67 2,9E-01 
PHPT1 0,54 4,7E-02 0,30 1,2E-02 0,48 8,2E-03 0,81 4,5E-01 0,57 3,5E-01 0,54 1,2E-01 
GBE1 0,41 4,4E-04 0,35 2,2E-02 0,91 7,3E-01 0,37 1,1E-02 0,74 3,0E-01 0,47 1,0E-01 
RABGAP1 0,19 1,7E-02 0,63 1,0E-01 0,99 9,4E-01 0,41 1,8E-03 0,59 9,8E-03 0,47 2,1E-03 
DTYMK 0,16 4,8E-03 0,38 1,8E-01 0,66 7,2E-02 0,79 1,3E-01 0,64 2,8E-02 0,66 1,2E-02 
DYNLT3 0,77 6,7E-01 0,24 1,4E-02 0,81 3,2E-01 0,27 9,8E-04 0,71 6,1E-02 0,52 1,5E-01 
SF3B5 0,23 5,7E-02 0,70 5,4E-01 0,58 1,6E-03 0,93 4,3E-01 0,58 3,2E-01 0,35 8,6E-02 
ARPC1A 0,29 1,3E-03 0,38 1,1E-01 0,86 2,8E-02 0,35 9,5E-02 0,83 8,3E-01 0,70 6,7E-01 
SULT2B1 0,30 8,7E-03 0,25 1,0E-02 0,97 8,8E-01 0,24 7,7E-03 0,99 9,8E-01 0,66 5,6E-01 
ARPC5 0,68 3,7E-01 0,44 8,6E-03 0,73 6,0E-02 0,67 1,7E-02 0,53 1,5E-01 0,39 1,3E-01 
DDX39A 0,18 1,6E-03 0,66 1,0E-02 0,88 2,2E-01 0,31 5,1E-02 0,62 6,5E-01 0,79 7,5E-01 
BZW2 0,70 2,2E-03 0,28 1,5E-02 0,60 1,4E-01 0,52 9,3E-02 0,72 1,2E-01 0,65 2,7E-02 
TPD52L1 0,63 3,8E-02 0,40 2,4E-03 0,48 1,3E-03 0,82 2,4E-01 0,47 5,8E-01 0,69 6,6E-01 
SHMT1 0,30 4,3E-04 0,76 4,7E-01 0,84 2,1E-01 0,41 6,5E-04 0,57 2,0E-03 0,62 5,4E-02 
CBX5 0,16 5,7E-05 0,70 1,0E-02 0,55 1,2E-02 0,82 8,2E-02 0,50 7,5E-02 0,80 1,6E-02 
LRPAP1 0,59 1,1E-02 0,33 5,8E-04 0,77 9,1E-02 0,60 1,1E-03 0,72 4,8E-01 0,53 8,0E-02 
SRSF2 0,26 1,1E-03 0,41 1,2E-03 0,76 6,7E-02 0,93 3,8E-01 0,46 3,3E-01 0,75 1,3E-01 
ARFGAP1 0,34 1,1E-02 0,27 5,3E-02 0,85 2,0E-01 0,55 2,0E-01 0,75 5,8E-01 0,81 5,8E-01 
FAM50A 0,19 1,7E-02 0,50 1,1E-02 0,68 4,1E-02 0,60 4,3E-03 0,86 2,3E-01 0,77 2,4E-02 
RBM4 0,17 3,2E-03 0,37 1,8E-03 0,74 9,3E-02 0,55 8,1E-03 0,82 4,9E-01 0,94 6,5E-01 
MAPT 0,58 2,9E-01 0,54 7,7E-03 0,44 8,0E-02 0,72 6,2E-01 0,69 3,2E-01 0,63 2,5E-01 
DNAJC8 0,11 2,1E-03 0,33 3,5E-03 0,81 3,2E-01 0,92 7,5E-01 0,56 1,9E-01 0,90 6,9E-01 
PPM1G 0,14 7,6E-03 0,57 3,1E-02 0,80 3,1E-03 0,45 1,6E-03 0,92 7,6E-01 0,78 8,5E-02 
MAGED2 0,53 2,5E-01 0,78 2,2E-01 0,85 1,3E-01 0,14 1,8E-03 0,63 2,0E-01 0,77 1,7E-01 
RMDN1 0,43 9,6E-04 0,28 3,2E-02 0,73 2,5E-02 0,58 3,1E-02 0,74 4,1E-01 0,94 6,0E-01 
CACYBP 0,13 1,8E-05 0,40 2,6E-04 0,88 8,8E-02 0,53 1,3E-04 0,80 2,8E-01 0,95 8,1E-01 
CBX1 0,22 9,9E-06 0,26 6,7E-05 0,69 4,2E-03 0,82 4,2E-01 0,91 6,1E-01 0,80 3,8E-02 
DKFZp686A1765 0,17 1,8E-02 0,17 3,2E-06 0,84 1,6E-01 0,96 6,3E-01 0,87 6,3E-01 0,72 1,5E-01 
PAFAH1B1 0,51 6,3E-02 0,62 2,2E-01 0,71 9,6E-03 0,50 5,7E-03 0,80 2,9E-01 0,58 9,6E-02 
ADI1 0,55 2,9E-03 0,85 1,7E-02 0,62 4,4E-02 0,83 1,3E-02 0,54 3,0E-02 0,40 7,6E-02 
ATOX1 0,69 7,0E-02 0,46 5,3E-03 0,55 1,8E-02 0,94 8,0E-01 0,78 7,3E-02 0,39 1,9E-01 
EDF1 0,44 2,5E-02 0,31 1,1E-01 0,91 4,9E-01 0,81 8,3E-01 0,79 7,5E-01 0,60 5,4E-01 
PRMT1 0,30 1,3E-05 0,60 5,7E-05 0,92 1,2E-01 0,52 8,1E-05 0,75 2,0E-01 0,78 8,0E-02 
YWHAE 0,57 5,0E-03 0,50 4,9E-04 0,67 4,5E-03 0,54 4,3E-04 0,83 5,4E-01 0,76 2,3E-01 
HNRNPH1 0,23 4,8E-05 0,66 3,0E-03 0,69 2,0E-02 0,70 3,7E-03 0,93 5,4E-01 0,66 1,9E-02 
PIN1 0,79 1,9E-01 0,66 1,3E-01 0,79 1,6E-01 0,49 1,4E-01 0,57 4,9E-01 0,59 5,3E-01 
PCNA 0,09 9,1E-04 0,92 5,4E-01 0,80 1,8E-01 0,59 2,3E-03 0,89 3,5E-01 0,61 5,4E-03 
KNS2 0,44 4,1E-03 0,50 5,8E-02 0,96 6,7E-01 0,68 9,8E-03 0,48 1,6E-01 0,88 6,1E-01 
RPA3 0,24 2,2E-02 0,68 4,2E-02 0,67 8,1E-02 0,55 1,7E-04 0,90 8,5E-01 0,91 7,6E-01 
STMN1 0,08 3,7E-03 0,72 1,1E-02 0,79 6,0E-02 0,75 7,9E-03 0,90 3,4E-01 0,73 3,3E-03 
SUCLA2 0,77 3,3E-02 0,58 2,5E-04 0,81 2,7E-02 0,66 1,7E-03 0,57 3,1E-01 0,60 2,9E-01 
HRSP12 0,59 4,1E-03 0,47 6,0E-03 0,57 4,6E-03 0,84 1,2E-01 0,98 9,1E-01 0,55 2,6E-03 
CBX3 0,24 4,5E-05 0,57 5,0E-04 0,85 8,0E-02 0,68 1,4E-03 0,90 7,2E-01 0,77 2,4E-01 
TRMT112 0,10 4,3E-03 0,87 6,4E-01 0,83 9,1E-02 0,92 5,8E-01 0,49 3,4E-01 0,82 2,4E-01 
GRB2 0,34 5,6E-04 0,42 2,3E-04 0,82 1,1E-01 0,80 1,3E-01 0,87 2,0E-01 0,81 4,5E-02 
TSFM 0,57 1,8E-01 0,62 6,5E-03 0,86 4,2E-02 0,47 5,5E-04 0,86 6,9E-01 0,70 2,3E-01 
RBM14 0,20 8,4E-03 0,80 1,5E-01 0,66 2,2E-02 0,79 1,8E-01 0,81 3,8E-01 0,81 1,4E-01 
HGS 0,68 4,6E-01 0,67 4,0E-01 0,94 6,5E-01 0,64 3,1E-01 0,56 2,3E-01 0,61 3,9E-01 
TACO1 0,40 3,7E-04 0,63 8,8E-03 0,89 1,1E-01 0,89 3,3E-01 0,77 1,9E-01 0,50 2,4E-02 
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NUMA1 0,14 1,2E-02 0,68 4,5E-05 0,83 4,5E-03 0,71 1,0E-03 0,82 4,0E-01 0,95 8,2E-01 
PSMG1 0,50 1,4E-01 0,51 5,4E-02 0,85 4,0E-01 0,73 6,2E-02 0,97 9,2E-01 0,57 1,7E-01 
TBCB 0,66 2,8E-02 0,47 2,2E-02 0,63 2,5E-02 0,83 1,2E-01 0,81 2,4E-01 0,73 1,2E-01 
DDX19B 0,49 3,4E-03 0,77 1,1E-01 0,77 5,6E-02 0,72 1,0E-02 0,47 3,7E-01 0,91 6,8E-01 
IDI1 0,71 1,0E-01 0,87 3,7E-01 0,88 3,1E-01 0,28 1,9E-04 0,86 6,1E-01 0,54 2,6E-02 
SRP9 0,45 1,1E-04 0,71 1,8E-02 0,65 6,0E-04 0,85 5,7E-03 0,76 3,8E-01 0,76 1,4E-01 
CPNE3 0,43 1,7E-05 0,67 5,2E-05 1,00 9,1E-01 0,27 2,0E-05 0,84 8,6E-02 0,97 5,1E-01 
WDR5 0,23 4,8E-03 0,99 9,8E-01 0,92 6,6E-01 0,80 1,0E-01 0,40 2,3E-01 0,84 3,5E-01 
GLOD4 0,63 1,1E-02 0,77 1,1E-02 0,83 9,9E-03 0,82 1,2E-01 0,70 5,5E-01 0,46 3,2E-01 
CAPZB 0,66 1,7E-03 0,49 1,0E-03 0,82 3,4E-02 0,63 3,0E-04 0,79 4,4E-01 0,82 1,2E-01 
DPM1 0,57 9,9E-03 0,61 1,0E-01 0,64 5,5E-02 0,59 5,2E-03 0,97 8,8E-01 0,84 4,2E-01 
PAIP1 0,47 1,7E-02 0,40 5,9E-02 0,89 3,0E-01 0,92 2,0E-01 0,66 9,8E-02 0,88 2,6E-01 
EIF3H 0,62 6,0E-02 0,56 3,2E-01 0,66 1,1E-02 0,79 3,3E-03 0,77 3,4E-01 0,84 2,7E-01 
PIR 0,43 9,2E-02 0,49 1,3E-01 0,84 6,1E-01 0,87 6,2E-01 0,78 4,2E-01 0,83 5,7E-01 
FH 0,48 8,9E-04 0,70 3,6E-04 0,68 6,6E-03 0,89 5,8E-02 0,89 6,3E-01 0,63 1,9E-02 
RBBP7 0,36 4,8E-04 0,76 1,9E-02 0,91 2,6E-01 0,69 3,5E-02 0,84 4,5E-01 0,71 6,2E-02 
PHF5A 0,47 1,2E-02 0,55 1,2E-01 0,71 8,8E-02 0,89 5,9E-01 0,82 7,7E-01 0,83 6,5E-01 
GGCT 0,59 1,7E-02 0,51 2,8E-03 0,85 1,5E-02 0,92 1,1E-01 0,77 2,2E-02 0,65 2,4E-03 
SLC9A3R1 0,61 2,0E-03 0,47 3,2E-04 0,91 1,1E-01 0,76 9,6E-03 0,83 2,4E-01 0,70 2,4E-03 
GDI1 0,97 5,3E-01 0,44 6,7E-04 0,80 2,7E-03 0,39 1,3E-05 1,00 9,9E-01 0,70 3,4E-02 
EIF3K 0,47 3,4E-03 0,94 5,7E-01 0,93 6,7E-01 0,71 3,0E-03 0,76 1,6E-01 0,51 2,9E-01 
PRKRA 0,80 6,2E-01 0,93 8,7E-01 0,49 2,1E-01 0,75 6,3E-01 0,48 5,6E-02 0,89 4,4E-01 
SMC1A 0,22 7,7E-02 0,94 4,5E-01 0,98 7,1E-01 0,76 3,1E-02 0,57 4,7E-01 0,92 3,5E-01 
BLVRA 0,88 1,9E-01 0,62 1,5E-02 0,86 1,8E-01 0,50 2,1E-03 0,82 1,0E-01 0,69 2,6E-02 
TOMM40 0,84 5,0E-01 0,70 3,7E-01 0,70 5,6E-01 0,47 1,0E-01 0,96 9,3E-01 0,72 6,5E-01 
PPP2R5E 0,50 8,5E-02 0,83 3,6E-01 0,88 3,6E-01 0,52 2,8E-01 0,78 2,2E-01 0,90 6,1E-01 
PSMB5 0,78 1,1E-01 0,94 5,3E-01 0,83 1,7E-01 0,76 1,5E-02 0,53 3,0E-01 0,58 1,7E-01 
ADK 0,59 6,3E-02 0,60 1,3E-01 0,67 1,1E-01 0,83 2,5E-01 0,95 7,8E-01 0,80 1,3E-01 
FKBP4 0,39 2,6E-05 0,64 2,7E-04 0,98 6,0E-01 0,65 1,7E-03 0,91 1,4E-01 0,87 8,3E-02 
CTPS2 0,83 3,9E-01 0,78 3,9E-01 0,91 6,4E-01 0,47 8,1E-02 0,94 6,2E-01 0,53 2,0E-01 
DCTPP1 0,40 2,2E-03 0,88 1,9E-01 0,74 1,3E-02 0,87 1,4E-01 0,89 7,3E-01 0,71 1,5E-01 
PSMB1 0,48 3,8E-02 0,66 1,3E-02 0,84 1,1E-01 0,74 6,3E-03 0,95 8,3E-01 0,82 2,2E-01 
C9orf78 0,46 2,0E-01 0,85 7,8E-01 0,64 2,4E-01 0,73 2,0E-01 0,85 5,6E-01 0,97 8,8E-01 
PSMB7 0,68 1,4E-02 0,78 6,2E-02 0,57 9,3E-03 0,76 2,6E-01 0,88 4,0E-01 0,82 2,9E-01 
PSMA1 0,55 1,1E-02 0,66 1,9E-03 0,85 1,8E-02 0,95 2,0E-01 0,78 4,9E-01 0,74 8,2E-02 
WDR61 0,63 8,4E-04 0,90 4,6E-01 0,93 4,5E-01 0,62 2,7E-02 1,00 9,9E-01 0,51 3,7E-02 
MYO6 0,99 9,5E-01 0,87 3,1E-01 0,73 5,8E-02 0,43 4,5E-04 0,93 1,1E-01 0,83 3,7E-02 
CCT8 0,61 3,5E-03 1,00 8,9E-01 0,95 1,9E-01 0,67 1,3E-03 0,81 5,8E-02 0,74 1,2E-02 
UBE2M 0,58 1,5E-03 0,74 8,6E-03 1,00 9,7E-01 0,67 2,3E-03 0,91 4,3E-01 0,99 9,1E-01 
GDI2 0,78 3,5E-03 0,73 5,7E-04 0,85 8,8E-04 0,67 8,3E-05 0,87 3,2E-01 0,98 8,7E-01 
MCTS1 0,69 2,4E-01 0,85 1,2E-01 1,00 9,9E-01 0,83 3,2E-01 0,65 2,1E-01 0,91 5,5E-01 
ABCF1 0,65 1,6E-02 0,79 1,1E-01 0,95 3,0E-01 0,94 4,1E-01 0,78 2,6E-01 0,82 2,0E-01 
SNX5 0,60 3,6E-02 0,86 7,3E-04 0,94 6,8E-01 0,98 9,1E-01 0,94 7,7E-01 0,64 2,5E-02 
SRP72 0,63 3,1E-02 0,70 9,8E-02 1,00 1,0E+0 0,90 2,0E-01 0,89 7,0E-01 0,84 4,4E-01 
TPT1 0,47 1,2E-03 0,79 1,1E-01 0,96 4,0E-01 0,93 2,6E-01 1,00 9,8E-01 0,82 1,8E-01 
AP1M2 0,68 4,4E-01 0,96 8,6E-01 0,87 1,8E-01 0,90 2,7E-01 0,74 3,3E-02 0,83 1,1E-01 
BUB3 0,52 1,5E-03 0,96 6,6E-01 0,90 2,6E-01 0,82 8,5E-03 0,90 6,1E-01 0,88 1,9E-01 
CSK 0,95 6,9E-01 0,96 7,6E-01 0,96 6,9E-01 0,56 6,2E-03 0,69 3,4E-02 0,89 1,1E-01 
 
Common down-regulated proteins. A student’s t-test with a FDR of 0.05 was performed 
to compare R3 with R0 and R5 with R0. The relative expression (RE) was calculated 
according to the following equation: 2t-test difference. A p-value < 0.05 was considered 
significant. 
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Supplementary table 2 (ST2): Common up-regulated proteins 




















SLC3A2 22,30 1,1E-05 26,11 6,2E-06 1,70 1,5E-01 10,27 2,5E-05 1,64 2,4E-02 1,22 1,6E-02 
ASS 10,66 1,1E-04 4,95 4,5E-04 2,05 9,0E-04 20,60 1,3E-07 1,03 9,7E-01 6,47 1,3E-02 
BCAS1 27,62 1,3E-06 2,56 4,4E-02 1,58 6,5E-02 4,57 2,2E-05 4,44 3,6E-02 2,05 1,4E-01 
KTN1 26,14 3,0E-05 7,21 2,5E-04 3,36 5,4E-03 2,93 8,6E-02 1,16 8,0E-01 1,02 9,7E-01 
TFF1 13,40 1,1E-02 1,95 2,6E-01 2,23 1,4E-01 7,41 1,4E-03 1,42 3,8E-01 4,52 1,6E-02 
SLC7A5 5,80 2,0E-02 1,72 4,4E-01 2,03 1,2E-01 10,92 1,7E-03 1,55 9,6E-02 1,13 6,8E-01 
S100P 3,86 6,4E-02 1,26 8,5E-01 3,96 9,1E-02 4,91 4,9E-02 2,38 1,1E-01 3,45 2,2E-02 
ABHD11 4,45 9,7E-03 2,13 3,5E-02 1,11 5,8E-01 2,47 1,1E-03 1,85 1,6E-01 2,19 7,3E-02 
LAD1 1,05 8,1E-01 1,90 1,1E-02 1,59 3,4E-02 6,02 5,7E-04 1,65 3,0E-01 1,65 4,1E-01 
PLEC 5,12 1,3E-07 2,56 2,6E-05 1,46 1,7E-04 1,27 8,6E-03 1,70 1,5E-03 1,71 1,1E-03 
CDK5 6,12 1,3E-02 2,34 8,0E-02 1,20 3,4E-01 1,18 5,3E-02 1,65 2,2E-01 1,04 8,6E-01 
TSTA3 4,57 1,7E-04 1,37 2,5E-01 1,50 4,9E-02 2,58 3,1E-04 1,30 1,1E-01 1,44 8,3E-02 
PKP3 1,34 1,2E-01 1,90 4,7E-02 1,44 4,6E-02 4,90 6,2E-04 1,92 2,8E-01 1,01 9,9E-01 
LAMP1 4,44 7,4E-03 1,01 9,7E-01 2,25 2,1E-02 1,06 8,4E-01 1,23 5,6E-01 1,71 1,8E-01 
ETHE1 3,67 7,9E-03 2,27 8,0E-03 1,52 3,7E-01 2,15 1,4E-01 1,03 9,2E-01 1,01 9,9E-01 
TXNRD1 2,08 3,0E-03 1,63 9,5E-03 2,14 1,6E-03 3,06 1,3E-03 1,16 5,8E-01 1,57 8,0E-02 
ANXA11 2,40 6,1E-05 2,67 4,1E-04 1,26 3,2E-03 1,43 1,9E-03 1,65 1,8E-02 1,85 2,3E-04 
CNN2 4,50 1,0E-02 2,10 5,6E-02 1,05 9,1E-01 1,33 5,2E-01 1,20 7,2E-01 1,02 9,6E-01 
EIF4A2 3,56 9,4E-02 1,07 8,4E-01 1,44 3,3E-01 2,16 3,6E-01 1,74 1,9E-01 1,09 7,8E-01 
ABAT 1,56 6,7E-02 1,51 3,2E-02 2,17 1,9E-02 1,93 7,5E-04 1,69 5,5E-02 2,00 1,4E-02 
SEC31A 2,81 5,4E-04 1,67 3,6E-03 1,46 1,1E-03 1,07 3,6E-01 1,09 6,8E-01 2,14 1,9E-04 
APEH 2,68 7,5E-05 1,93 1,8E-03 1,32 6,0E-03 1,08 4,0E-01 1,32 1,7E-01 1,65 3,6E-02 
NAMPT 1,93 1,1E-02 2,24 4,4E-03 1,13 1,6E-01 2,22 3,9E-03 1,16 5,9E-01 1,22 2,8E-01 
TRMT10C 1,21 1,6E-01 2,23 1,9E-04 1,57 1,4E-02 1,70 1,6E-04 1,14 8,5E-01 1,78 3,0E-01 
ITGB1 2,91 3,2E-03 1,31 2,0E-01 1,64 4,0E-02 1,27 6,8E-01 1,01 9,6E-01 1,47 1,5E-01 
C9orf142 1,27 4,5E-01 1,01 9,7E-01 1,48 1,8E-01 1,15 8,1E-01 1,95 7,7E-02 2,59 6,0E-03 
PDIA3 2,42 1,5E-05 1,15 1,0E-02 1,04 6,4E-01 2,05 5,1E-04 1,36 9,7E-02 1,41 4,7E-02 
LDHA 3,11 3,3E-04 0,97 7,4E-01 1,21 7,6E-02 1,41 2,3E-03 1,16 4,6E-01 1,52 1,4E-01 
CDC42 1,23 5,9E-01 1,55 1,9E-02 2,77 1,4E-01 1,46 5,4E-01 1,14 8,0E-01 1,12 8,3E-01 
ERO1L 3,06 1,4E-04 1,11 1,1E-01 1,23 3,6E-02 1,22 3,2E-02 1,30 1,8E-01 1,32 1,5E-01 
MDH2 2,32 2,4E-04 1,65 2,0E-03 1,02 6,3E-01 1,56 1,1E-03 1,27 2,5E-01 1,16 3,9E-01 
TXNDC5 2,14 1,6E-03 1,42 3,0E-03 1,58 6,7E-05 1,36 1,1E-01 1,29 6,6E-02 1,15 5,9E-01 
CAT 1,80 2,0E-02 1,72 2,1E-03 1,37 3,3E-02 1,52 4,6E-02 1,49 5,5E-02 1,02 8,4E-01 
EPS8L2 1,78 1,7E-02 1,25 3,1E-01 1,78 7,7E-03 1,24 1,6E-01 1,35 2,0E-01 1,32 3,6E-01 
HPRT1 1,42 4,9E-02 1,97 3,0E-03 1,02 8,0E-01 2,00 2,4E-04 1,11 6,1E-01 1,14 3,9E-01 
GANAB 2,36 2,9E-04 1,49 1,4E-02 1,08 1,6E-01 1,24 1,2E-02 1,05 7,9E-01 1,23 2,0E-01 
PES1 1,10 8,6E-01 1,48 4,8E-01 1,13 7,0E-01 1,53 2,4E-01 1,60 4,3E-01 1,42 5,7E-01 
UQCRC1 1,74 1,3E-03 1,26 4,1E-02 1,40 1,8E-03 1,02 7,4E-01 1,36 1,5E-01 1,37 1,8E-02 
PDIA6 1,77 2,1E-03 1,05 6,4E-01 1,05 6,8E-01 1,59 1,2E-02 1,19 6,0E-01 1,13 7,0E-01 
VPS35 1,37 1,3E-02 1,52 1,2E-03 1,29 3,8E-02 1,04 5,9E-01 1,46 1,2E-02 1,05 4,9E-01 
VARS 1,22 3,5E-01 1,63 7,9E-03 1,10 2,0E-01 1,26 1,8E-02 1,02 7,8E-01 1,43 5,6E-03 
UQCRC2 1,73 1,2E-03 1,08 4,9E-01 1,21 4,3E-03 1,13 5,2E-03 1,02 9,2E-01 1,23 1,4E-02 
 
Common up-regulated proteins. A student’s t-test with a FDR of 0.05 was performed 
to compare R3 with R0 and R5 with R0. The relative expression (RE) was calculated 
according to the following equation: 2t-test difference. A p-value < 0.05 was considered 
significant. 
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Supplementary table 3 (ST3): Potential common drivers of chemoresistance 
Down 
relative 
expression SD Biological process 
NMD3 0.43 0.20 RNA biosynthesis 
STAU1 0.48 0.25 cellular response to oxidative stress 
PRPF6 0.54 0.17 RNA splicing 
UGDH 0.55 0.40 metabolism 
TMSB4X 0.57 0.24 TNF-signaling, chemotaxis. actin filament organization 
RBM4 0.57 0.19 cell differentiation, RNA splicing 
BZW2 0.58 0.19 cell differentiation 
PHPT1 0.59 0.24 cell motility, actin filament organization 
ISOC1 0.59 0.33 metabolism 
LRPAP1 0.59 0.15 receptor mediated endocytosis 
SHMT1 0.60 0.21 folic acid metabolic process 
CBX5 0.61 0.30 transcription 
PARP1 0.61 0.21 DNA repair, cellular response to oxidative stress 
CSE1L 0.63 0.35 apoptosis, cell proliferation 




expression  SD Biological process 
SLC3A2 12.72 14.36 cell growth, metabolism. glucose transport 
ASS 8.83 9.21 metabolism 
PHGDH 3.82 4.85 metabolism, G1 to G0 transition 
PPL 2.71 1.44 cytoskeleton organization 
PCK2 2.48 1.60 metabolism, cellular response to TNF 
ABHD11 2.38 1.25 hydrolase 
PLEC 2.23 1.13 RNA binding 
TSTA3 2.17 1.18 metabolism, oxidation reduction process 
TXNRD1 1.84 0.63 cell redox homeostasis 
ANXA11 1.79 0.18 cell cycle, cell division 
ABAT 1.79 0.17 cellular response to drug 
TFRC 1.91 1.32 cellular response to drug 
RAB7A 1.80 0.73 endocytosis 
APEH 1.60 0.31 proteolysis 
SEC31A 1.61 0.40 protein transport 
Treated cells (R3 and R5) were compared with untreated cells (R0) and the relative 
expression values normalized to R0 are depicted as mean and SD of all MEAs. 
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3. GRK5 REGULATES BREAST CANCER CELL 
MIGRATION 
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3.1 ABSTRACT 
Sunitinib is a multispecific kinase inhibitor and one of its targets is the kinase GRK5, 
which is regulating a multitude of G protein-coupled receptors (GPCRs). In this study 
we demonstrate that a decreased GRK5 expression induced by knock-down 
experiments or sunitinib treatment hampers the migration of cancer cell lines. A 
proteomic analysis revealed many pathways related to cell migration which were down 
regulated upon the GRK5 knock-down. Furthermore, we found in MDA-MB-231 breast 
cancer cells that the inhibition of migration is mediated by the GPCR gastrin releasing 
peptide receptor (GRPR) leading to a reduced expression of migration regulating 
downstream targets like CDC42 and ROCK1. An in-silico Kaplan Meier analysis revealed 
that GRK5 and GRPR overexpression reduces the distant metastasis free survival in 
triple-negative breast cancer (TNBC) patients. Thus, we suggest a novel anti-migratory 
effect of impaired GRK5 expression which induces a negative feedback loop on GRPR 
signaling. 
3.2 INTRODUCTION 
G protein-coupled receptors (GPCRs) are the largest group of cell surface receptors in 
humans and comprise of more than 800 members (Pierce et al., 2002). They are also 
known as seven-transmembrane receptors and are involved in many physiological 
processes like neurotransmission, metabolism, immune response, regulation of blood 
pressure and cardiac activity (Dorsam and Gutkind, 2007). Therefore, a tight regulation 
of these signaling cascades is of great importance to avoid disease formation.  
One regulatory protein class are the AGC kinases to which the G protein-coupled 
receptor kinase (GRK) family belongs. These seven serine-threonine kinases can be 
categorized according to their structural properties into three subgroups: the visual 
subfamily (GRK1, GRK7), the GRK2 subfamily (GRK2, GRK3) and the GRK4 subfamily 
(GRK4, GRK5, and GRK6) (Premont et al., 1995; Siderovski et al., 1996). In general, 
all GRKs regulate the GPCR signaling by phosphorylating agonist-activated GPCRs in 
the third cytoplasmic loop and/or the C-terminal tail.  
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This leads to the recruitment of β-arrestins and subsequently to the uncoupling of the 
G proteins. This process is termed GPCR desensitization (Gurevich et al., 2012; 
Komolov and Benovic, 2018). β-arrestins are also known to function as scaffold 
proteins that facilitate the internalization of GPCRs thus resulting in the recycling or 
lysosomal degradation of the receptor (Shenoy and Lefkowitz, 2011). Due to the fact 
that the seven GRKs regulate more than 800 GPCRs it is obvious that GRKs affect the 
signal transduction of complex signaling cascades which comprise of more than one 
GPCR. Therefore, aberrant expression of these kinases leads to malfunction of several 
GPCRs and consequently to diseases like diabetes, hypertension, cardiac dysfunction, 
Alzheimer’s disease and cancer (Gurevich et al., 2012; Pierce et al., 2002). 
Tumorigenesis was shown to be influenced mainly by GRK2 and GRK5 (Gambardella 
et al., 2016; Nogues et al., 2018; Yu et al., 2018). These kinases often function as 
oncogenes in glioblastoma (Kaur et al., 2013), prostate (Chakraborty et al., 2014; 
Gambardella et al., 2016), pancreas (Buchholz et al., 2015), non-small-cell lung (Jiang 
et al., 2018) and breast cancer (Nogues et al., 2016).  
According to the Human Protein Atlas, 50% of the analyzed breast cancer patients 
possessed elevated GRK2 or GRK5 expression (Uhlen et al., 2005; Uhlen et al., 2017), 
whereas the latter was shown to result in even worse prognosis concerning the 5-
years survival rate. Nevertheless, the role of GRK5 in breast cancer has not been 
studied and the mechanism of action remains rather unclear. Breast cancer affects one 
of eight women during their lifetime and is estimated to be the second leading cause 
of cancer deaths in women in the United States in 2018 (American Cancer Society, 
2018). Therefore, it is of great importance to identify novel predictive biomarkers and 
druggable targets associated with this disease. 
Therefore, the aim of this study was to elucidate the function of GRK5 in breast cancer 
and investigate whether the targeting of GRK5 could have a beneficial effect on cancer 
treatment. Sunitinib is the most potent, approved small-molecule inhibitor (SMI) 
targeting GRK5 (Anastassiadis et al., 2011; Gao et al., 2013). Since 2006 sunitinib is 
approved by the FDA for the treatment of gastrointestinal stromal tumors, which are 
refractory or intolerant to imatinib treatment, and for advanced, metastatic renal cell 
carcinoma (mRCC) (Goodman et al., 2007; Rock et al., 2007).  
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This multispecific kinase inhibitor was shown to mainly inhibit the receptor tyrosine 
kinases (RTKs) vascular endothelial growth factor receptor (VEGFR) and platelet 
derived growth factor receptor (PDGFR) (Polyzos, 2008) thereby blocking the 
angiogenesis of tumors.  Thus, we additionally investigated the effect of sunitinib on 
GRK5 and breast cancer cells in vitro. 
3.3 RESULTS 
3.3.1 ANALYSIS OF DIFFERENT BREAST CANCER CELL LINES REVEALS INCREASED GRK5 
EXPRESSION IN MESENCHYMAL CELLS 
To evaluate the expression level of GRK5 in breast cancer, a qPCR analysis was 
performed. The cell lines were grouped according to their morphology. Spindle-like cell 
lines were regarded as mesenchymal (MDA-MB-415, BT-549, MDA-MB-435s, HS-578T, 
MDA-MB-231) and cobblestone-like growing cells were considered as epithelial cells 
(MCF-7, BT-474, ZR-75, SKBR-3, MDA-MB-361).  
We observed that GRK5 is significantly higher expressed in mesenchymal-like breast 
cancer cells and that MDA-MB-231 cells, a metastatic, triple-negative breast cancer cell 
line, showed the highest GRK5 expression level of all analyzed cell lines (Fig. 8A). A 
similar expression pattern was observed by western blot analysis in an additional panel 
of cancer cell lines (Supplementary Fig. S3). Therefore, MDA-MB-231 was chosen as 
model for further experiments. The expression levels of the other GRK4-family 
members, GRK4 and GRK6, were analyzed in MDA-MB-231 cells. Here, GRK6 is equally 
highly expressed as GRK5, whereas GRK4 shows a very low expression level (Fig. 8B). 
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3.3.2 CHARACTERIZATION OF AN INDUCIBLE SHGRK5 KNOCKDOWN IN MDA-MB-
231 ELUCIDATES THE IMPACT OF GRK5 ON CELL VIABILITY, APOPTOSIS, 
MIGRATION AND INVASION IN BREAST CANCER 
In order to further investigate the function of GRK5 in triple-negative breast cancer 
(TNBC), MDA-MB-231 cells stably expressing a doxycycline inducible shGRK5 were 
generated (termed MDA-MB-231 TRIPZ-shGRK5 in the following). As a gene coding 
for RFP is localized downstream of the doxycycline (DOX) inducible promotor, a 
fluorescence signal indicates shGRK5 expression upon DOX induction (Fig. 8C). 
Subsequently, we investigated the mRNA expression level of GRK5 in MDA-MB-231 
TRIPZ-shGRK5 and MDA-MB-231 wild-type (wt) cells 72 h after inducing with DOX to 
determine the knockdown (KD) efficiency (Fig. 8C). 
Moreover, possible compensatory effects of GRK4-family members were investigated 
in a time-dependent manner after DOX treatment and could be excluded as the mRNA 
expression levels of GRK4 and GRK6 remain similar after the GRK5 KD (Fig. 8D).  
To elucidate the physiological impact of GRK5 KD in TNBC development and 
progression, cell viability and apoptosis induction were measured 90 h after DOX 
stimulation in MDA-MB-231 TRIPZ-shGRK5 cells. We observed that the GRK5 KD 
neither reduces the cell viability nor increases the apoptosis rate (Supplementary Fig. 
S4). 
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Figure 8. Expression analysis of GRK5 and characterization of MDA-MB-231 TRIPZ-shGRK5 which were 
generated by Dr. Bojan Ljepoja. (A) Expression analysis of GRK5 in different breast cancer cell lines 
utilizing qPCR. The values are depicted as mean + SD in the left panel and as median + range in the 
right panel. Student’s t-test was used for statistical evaluation. (B) Expression analysis of GRK4 family 
members in MDA-MB-231 wild-type cells.  
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(C) Characterization of MDA-MB-231 TRIPZ-shGRK5. GRK5 expression analysis and fluorescence 
microscopy pictures upon induction with 5 µg/ml doxycycline for 72 h. This cell line was generated by 
Bojan Ljepoja. (D) Expression analysis of GRK4 family members at the indicated time points upon 
induction with 5 µg/ml doxycycline. N = 3, * p < 0.05, ** p < 0.01, *** p < 0.001 
 
3.3.3 PROTEOMIC ANALYSIS AND BOYDEN CHAMBER EXPERIMENTS REVEAL IMPACT OF 
GRK5 ON CANCER CELL MIGRATION 
To investigate whether GRK5 influences breast cancer development and progression 
in general, a proteomics approach utilizing LC-MS was performed. Therefore, MDA-
MB-231 TRIPZ-shGRK5 were seeded in quintuples, twice induced with doxycycline and 
harvested after 90 h (Fig. 9A). The subsequent proteomic analysis revealed 2220 
proteins that were identified at least three times in induced and not-induced samples. 
The following gene set enrichment analysis (GSEA) utilizing Gene Ontology Biological 
Process (GO_BP) elucidated up and down regulated signaling pathways upon GRK5 
KD. By clustering the resulting pathways in signaling cascades important for 
tumorigenesis it was observed that a decrease in GRK5 expression primarily leads to a 
down regulation of cell motility pathways (Fig. 9B).  
To validate the effect of GRK5 on cancer cell migration, boyden chamber experiments 
with and without matrigel coating were performed. Thereby, we showed that GRK5 
KD significantly hampers both migration and invasion in TNBC cells (Fig. 9C and D). 
Additionally, a KD by a pool of GRK5 siRNAs was performed in another breast cancer 
(HS-578T) and two prostate cancer cell lines (DU-145, PC-3) (Fig. 9E) and its effect 
on cancer cell migration was confirmed (Fig. 9F). 
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Figure 9. Proteomics, migration and invasion analysis of MDA-MB-231 TRIPZ-shGRK5. (A) Scheme of 
proteomics analysis. Cells were seeded in quintuples and stimulated with 5 µg/ml doxycycline or control 
every 48 h for 90 h. Subsequently a proteomic analysis utilizing LC-MS was performed by Dr. Thomas 
Fröhlich and Dr. Georg J. Arnold, Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, 
LMU. (B) Overview of up and down regulated pathways revealed by GSEA. Gene ontology biological 
process was utilized as dataset. (C) Migration analysis of MDA-MB-231 TRIPZ-shGRK5 90 h upon 
stimulation with doxycycline or control using a boyden chamber migration assay. Representative pictures 
are shown. (D) Invasion analysis utilizing matrigel coated boyden chambers 90 h after stimulation 5 
µg/ml doxycycline or control. (E) Western blot analysis of HS-578T, DU-145 and PC-3 72h upon siGRK5 
KD. The presented blots were cropped (F) Migration analysis of HS-578T, DU-145 and PC-3 90 h upon 
transfection with sc.ctr. or siGRK5. Relative migration or invasion is shown as mean + SD normalized to 
not induced or sc.ctr. transfected samples (N = 3). A two-tailed Student’s t-test was performed. * p < 
0.05, ** p < 0.01, *** p < 0.001 
 
3.3.4 GRK5 KD HAMPERS CHEMOTAXIS OF MDA-MB-231 CELLS TOWARDS 
BOMBESIN   
To identify the underlying signaling pathways, different chemoattractants were 
analyzed in a boyden chamber experiment with respect to their pro-migratory activity 
on MDA-MB-231 cells. Moreover, it was investigated whether this effect can be blocked 
or reduced by a siGRK5 KD. We demonstrate that only bombesin, bradykinin and 
insulin increased the migratory behavior of MDA-MB-231 cells, which can be 
significantly decreased by a GRK5 KD in the case of bradykinin and bombesin (Fig. 10A 
and B). As bombesin shows the most significant change in migratory behavior this 
ligand was analyzed further. 
The impact of bombesin on the migration of TNBC cells was also examined in MDA-
MB-231 TRIPZ-shGRK5 cells to exclude transfection artefacts, as transfection agents 
could influence cancer cell migration. Here, the chemotactic effect of bombesin was 
also reduced by shGRK5 (Fig. 10C). Furthermore, the influence of GRK5 and bombesin 
on the invasiveness of MDA-MB-231 TRIPZ-shGRK5 cells was investigated. As depicted 
in Fig. 10D, a reduction of GRK5 expression leads to a decreased invasion of TNBC 
cells towards a bombesin gradient. 
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Figure 10. Evaluation of chemoattractants with regard to their migration stimulating capabilities in 
MDA-MB-231 cells and the blockage thereof by GRK5 KD. (A) Western blot analysis of MDA-MB-231 72h 
upon siGRK5 KD. The presented blots were cropped. (B) Screening of different chemoattractants. The 
indicated ligands were added in the lower well at the following concentrations: Angiotensin 100 nM, 
Bombesin 200 nM, Bradykinin 5 µM, Endothelin 100 nM, Glucose 4.5 g/ml, Insulin 10 µg/ml, LPA 10µM. 
Relative migration values are depicted as mean + SD and are normalized to untreated, sc.ctr. 
transfected cells (N = 3). (C) Analysis of migratory behavior of MDA-MB-231 TRIPZ-shGRK5 cells 90 h 
upon induction with 5 µg/ml doxycycline or control with or without stimulation with 200 nM bombesin. 
Cells were stained with crystal violet and representative pictures are shown (N = 3).  
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(D) Invasion analysis of MDA-MB-231 TRIPZ-shGRK5 90 h upon induction with 5 µg/ml doxycycline or 
control with or without stimulation with 200 nM bombesin. Cells were stained with crystal violet and 
representative pictures are shown. Values are depicted as mean + SD and are normalized to not 
induced, not stimulated samples (N = 3). One-way ANOVA with Dunnett’s Multiple Comparison Test and 
multiple t-tests utilizing two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli was used 
for statistical analysis. * p < 0.05, ** p < 0.01, *** p < 0.001 
 
3.3.5 REDUCTION IN GRPR EXPRESSION BY GRK5 KD DECREASES CHEMOTAXIS OF 
MDA-MB-231 TOWARDS BOMBESIN 
The gastrin releasing peptide receptor (GRPR) is the cellular receptor of bombesin and 
therefore, its expression levels were analyzed in different breast cancer cells to confirm 
its impact on migration. Fig. 11A shows that GRPR is significantly higher expressed in 
mesenchymal-like breast cancer cells. Subsequently, the influence of the GRK5 KD on 
the GRPR signaling pathway was investigated. Here, we observed that the autocrine 
activation loop of the GRPR signaling is hampered upon GRK5 KD since the mRNA level 
of GRPR as well as that of its natural ligand GRP was reduced (Fig. 11B). A GRPR KD 
on the other hand had no impact on the GRK5 expression (Supplementary Fig. S5). 
Next, the impact of GRPR on cell migration of TNBC was examined. We detected that 
GRPR KD reduces the migratory behavior of MDA-MB-231 to a similar extent as a GRK5 
KD (Fig. 11C). In order to determine whether GRPR is the only GPCR that is regulated 
by GRK5 and thus is responsible for the reduced chemotaxis towards bombesin, cells 
were transfected with both siGRK5 and siGRPR. As depicted in Fig. 4D this double-KD 
is not further reducing the migration of MDA-MB-231 cells indicating that GRPR is the 
main player in the chemotactic process which is regulated by GRK5. 
By comparing the measured migration data, we observed a constant reduction in the 
migratory behavior of 25-30 % upon GRK5 KD, GRPR KD and the double KD of GRK5 
and GRPR emphasizing the key role of GRPR in GRK5 mediated migration. 
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Figure 11. Correlation of GRK5 and GRPR and their impact on migration. (A) Expression analysis of 
GRPR in different breast cancer cell lines utilizing qPCR. The values are depicted as mean + SD in the 
left panel and as median + range in the right panel. Student’s t-test was used for statistical evaluation. 
(B) Expression analysis of GRK5, GRPR and GRP 90 h upon induction with 5 µg/ml doxycycline utilizing 
qPCR. Values are depicted as mean + SD. Two-tailed Student’s t-test was utilized for statistical 
evaluation. (C) Migration analysis of MDA-MB-231 cells 90 h upon transfection with sc.ctr. or siGRPR 
with and without stimulation with 200 nM bombesin. Representative pictures of the crystal violet staining 
are shown at the right panel. Relative migration values are depicted as mean + SD and normalized to 
sc.ctr. transfected, not stimulated samples. (N = 3). (D) Migration analysis of MDA-MB-231 cells 90 h 
after transfection with sc. ctr. or siGRK5 and siGRPR, with or without bombesin stimulation using a 
boyden chamber assay. Representative pictures of the crystal violet staining are shown. The relative 
migration values are normalized to sc.ctr. transfected, not stimulated samples and depicted as mean + 
SD (N = 3). For statistical evaluation one-way ANOVA with Dunnett’s Multiple Comparison Test was 
used. * p < 0.05, ** p < 0.01, *** p < 0.001 
 
3.3.6 SUNITINIB TREATMENT HAMPERS CELL MIGRATION BY REDUCING THE 
EXPRESSION OF GRK5 AND GRPR 
Sunitinib is the most potent, approved GRK5 inhibitor (Anastassiadis et al., 2011; Gao 
et al., 2013). To evaluate the clinical relevance of our findings MDA-MB-231 cells were 
treated with this SMI and its effect on cell viability, migration, GRK5 and GRPR 
expression as well as GRPR signaling was investigated. Fig. 12A shows that 5 µM 
sunitinib treatment reduces the cell viability of TNBC cells. Therefore, only lower, non-
toxic concentrations were utilized for the cell migration analysis. Here, we 
demonstrated that 1 µM sunitinib treatment significantly reduces the migration of 
breast cancer cells. A similar effect was detected for the GRK5 KD. The impact of 
sunitinib treatment on the expression of GRK4-family members was investigated. 
Sunitinib significantly reduces the expression only of GRK5 - no significant expression 
changes were observed for GRK4 and GRK6 (Fig. 12B). Additionally, sunitinib 
significantly decreases the expression of GRPR and down-stream targets like CDC42 
and ROCK1 (Fig. 12C). To investigate whether the GRK5 inhibition, which leads to 
impaired GRPR signaling and eventually reduced migration, has an impact on patient 
survival, we analyzed patient data in silico. The Kaplan-Meier Plotter (Gyorffy et al., 
2010) revealed that GRK5 and GRPR overexpression shows a tendency to reduce the 
distant metastasis free survival (DMFS) in TNBC patients (Fig. 12D). Therefore, we 
hypothesize that sunitinib treatment of TNBC prolongs DMFS and thus could improve 
the patient outcome (Fig. 13). 
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Figure 12. Analysis of clinical impact. (A) MDA-MB-231 cells were treated for 90 h with the indicated 
concentrations of sunitinib. Left panel: Cell viability measurement by CellTiter-Glo luminescent cell 
viability assay. Right panel: Migration analysis by boyden chamber. Values are presented as mean + SD 
and are normalized to untreated cells. For statistical evaluation one-way ANOVA with Dunnett’s Multiple 
Comparison Test was used (N = 3).  
3. GRK5 REGULATES BREAST CANCER CELL MIGRATION 
60 
DISSERTATION ANN-KATRIN SOMMER 
(B) Gene expression analysis of GRK4-family members. Values are presented as mean + SD and are 
normalized to untreated cells. For statistical evaluation multiple t-tests utilizing two-stage linear step-up 
procedure of Benjamini, Krieger and Yekutieli, were used (N = 3). (C) Gene expression of GRPR and 
GRPR down-stream signaling components. Values are presented as mean + SD and are normalized to 
untreated cells. For statistical evaluation student’s t-test (left panel) and multiple t-tests (right panel) 
utilizing two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, were used. (D) Kaplan 
Meier analysis (Gyorffy et al., 2010) of GRK5 and GRPR overexpression. The influence on distant 
metastasis free survival (DMFS) in breast cancer patients with basal like tumors is depicted. * p < 0.05, 
** p < 0.01, *** p < 0.001 
 
 
Figure 13. Supposed mechanism. GRK5 phosphorylates the GRPR upon bombesin binding. This leads 
to the activation of GRPR down-stream signaling and subsequently to the transcription of proteins like 
FLNA, PLAU and CD47. The final consequence is the maintenance of cell polarity and tension enabling 
cell migration which could be therapeutically exploited by inhibiting this pathway with sunitinib 
treatment. 
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3.4 DISCUSSION 
Previous studies have shown that GRK5 affects the migration of prostate cancer via 
moesin (Chakraborty et al., 2014) and of non-small cell lung cancer cells via vinculin 
(Jiang et al., 2018). However, the function of GRK5 in breast cancer and the involved 
GPCRs remain unclear. In this study, a breast cancer cell line screen revealed that 
GRK5 is mainly expressed in TNBC cell lines, which possess a mesenchymal like 
phenotype and are able to migrate. Accordingly, the GRK5 KD by a pool of siRNAs and 
the inducible shRNA in MDA-MB-231 cells reduced cell migration and invasion as well 
as the expression of proteins involved in cell migration pathways. In order to uncover 
the responsible GPCRs different ligands were used as chemoattractants. Here, 
bombesin stimulation, amongst others, resulted in significantly increased cell migration 
which can be blocked by the GRK5 KD, mediated by both, the siRNA and shRNA 
approach. This finding led to the assumption that GRK5 interferes with the GRPR 
signaling pathway, as bombesin, an artificial ligand, binds and activates the GRPR 
(Gonzalez et al., 2008; Moreno et al., 2016; Ramos-Alvarez et al., 2015). GRPR is an 
important receptor in breast cancer and is overexpressed in up to 96 % of breast 
cancer patients (Dalm et al., 2015). An elevated GRPR expression in breast cancer 
tissue worsens the prognosis (Uhlen et al., 2005; Uhlen et al., 2017). Our expression 
analysis in different breast cancer cell lines revealed that GRPR is significantly higher 
expressed in mesenchymal like breast cancer cell lines and correlates with the GRK5 
expression. The subsequent qPCR analysis of GRPR and its natural ligand GRP upon 
GRK5 KD displayed decreased GRPR and GRP expression. Vice versa the KD of GRPR 
had no influence on the GRK5 expression. Thus, the GRK5 KD hampers the autocrine 
signaling mechanism by inhibiting the expression of both the endogenous ligand as 
well as that of the corresponding receptor. GRPR is the sole receptor involved in the 
chemotaxis of cancer cells towards the ligands GRP/bombesin (Chao et al., 2009; 
Jaeger et al., 2017). The decrease in its expression by GRK5 KD therefore directly 
impacts the migration of cancer cells. It was previously shown that the increase in 
GRPR signaling leads to enhanced cancer cell migration and invasion in various cancer 
types (Nagakawa et al., 2001; Tell et al., 2011).  
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However, there are many more GPCRs involved in migration like the bradykinin 
receptor (Seifert and Sontheimer, 2014), angiotensin receptor (Kim et al., 2018b), 
endothelin receptor (Shi et al., 2017) and thrombin receptor (Vianello et al., 2016).Our 
ligand screen however revealed, that only bradykinin and bombesin stimulated 
migration was hampered by the GRK5 KD and are thus the crucial pathways influenced 
by GRK5. Moreover, we performed a KD with siRNAs against GRPR and a double KD 
with siRNAs against GRK5 and GRPR, and investigated the effect on migration. It was 
shown that all analyzed KD experiments with siGRK5, shGRK5, siGRPR and the double 
KD of GRK5/GRPR, had the same impact on cell migration. We therefore conclude, 
that the GRPR signaling pathway is an important migratory mechanism which is 
regulated by GRK5. The knock-down of GRK5 activates a negative feedback loop by 
attenuating the expression of GRP and GRPR, finally leading to reduced migration in 
our in vitro system. 
To evaluate the clinical significance of our findings, TNBC cells were treated with 
sunitinib, the most potent, FDA approved GRK5 inhibitor (Anastassiadis et al., 2011; 
Gao et al., 2013). We observed that sunitinib hampers the migration of MDA-MB-231 
cells at non-toxic doses. Previously, it was already shown that sunitinib hampers cell 
migration in different cancer subtypes but only at toxic doses (Andrae et al., 2012; 
Chinchar et al., 2014). Thus, these studies hardly allow a clear discrimination between 
cytotoxicity and migration. Furthermore, we performed an expression analysis of all 
GRK4-family members, GRPR and GRPR down-stream signaling components to 
elucidate whether the effect of sunitinib on cancer cell migration is based on the GRK5-
GRPR signaling cascade. As sunitinib is a multispecific kinase inhibitor this SMI inhibits 
besides GRK5 e.g. VEGFR and PDGFR (Anastassiadis et al., 2011; Andrae et al., 2012; 
Bender and Ullrich, 2012; Gao et al., 2013). Our results show, that sunitinib treatment 
not only inhibits GRK5 but also significantly reduces its expression whereas GRK4 and 
GRK6 expression remains stable. Additionally, we observed that sunitinib treatment 
reduced the expression of GRPR and down-stream signaling components. As GRPR is 
no reported target gene of sunitinib, it is likely that sunitinib decreases the expression 
of GRK5 thus indirectly leading to the downregulation of GRPR and its downstream 
targets RAC1, CDC42 and ROCK1.  
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The latter three proteins belong to the Rho GTPase family and are crucial players in 
cell migration (Friedl et al., 2014; Zegers and Friedl, 2014). Previous studies have 
shown that increased CDC42 and ROCK1 expression directly correlates with elevated 
actomyosin contractility, actin turnover and actin polymerization and eventually 
facilitate the migration of cancer cells (Bray et al., 2013). Thus, sunitinib treatment of 
TNBC cells might reduce their ability to migrate by down regulating GRK5 resulting in 
the decreased expression of GRP, GRPR, CDC42 and ROCK1. Moreover, this finding 
might mechanistically explain the prolonged survival of mRCC patients upon sunitinib 
treatment (Tannir et al., 2017). Here, this therapy not only reduces the metastatic 
burden but also avoids the development of new metastases and thus leads to an 
improved patient outcome. 
Taken together, this study shows that GRK5 KD hampers the chemotaxis of MDA-MB-
231 cells towards bombesin by down regulating the GRPR. Furthermore, we observed 
that treatment with the multispecific kinase inhibitor sunitinib decreases the cancer cell 
migration by reducing the GRK5 expression levels resulting in attenuated GRPR 
signaling, depicting a novel mechanism of action of a well-known drug. We therefore 
encourage further studies on this mechanism and speculate, that the implementation 
of sunitinib in TNBC treatment regimen could be a promising option to reduce the 
formation of metastases which is still one of the major obstacles in the treatment of 
TNBC.  
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3.5 MATERIAL AND METHODS 
3.5.1 REAGENTS 
Doxycycline hyclate was purchased from Sigma-Aldrich (St. Louis, Missouri, USA) 
(cat.nr. D9891). Bombesin acetate salt hydrate (cat.nr. B4272), Bradykinin acetate salt 
(cat.nr. B3259), human angiotensin II (cat.nr. A9525), endothelin I (cat.nr. E7764), 
lysophosphatidic acid sodium salt (cat.nr. L7260), human thrombin (cat.nr. T4393), 
glucose (cat.nr. D7021) and human insulin (cat.nr. I3536) were purchased from 
Sigma-Aldrich. Sunitinib malate was purchased from Sigma-Aldrich (cat.nr. PZ0012). 
Lipofectamine 3000 was purchased from ThermoFisher Scientific (Waltham, 
Massachusetts, USA) (cat.nr. L3000008). 
3.5.2 CDNA OF DIFFERENT BREAST CANCER CELL LINES 
The cDNA of the different breast cancer cell lines was a kind gift of Axel Ullrich’s lab. 
3.5.3 CELL CULTURE 
MDA-MB-231 cells were obtained from DSMZ (Braunschweig, Germany) MDA-MB-231 
TRIPZ-shGRK5 were generated in our lab and both were cultured in DMEM high 
glucose supplemented with 10% fetal calf serum (FCS, Gibco) at 37°C and 5% CO2. 
HS-578T, DU-145 and PC-3 were obtained from ATCC (Manassas, Virginia, USA) and 
cultured according to manufacturer’s instructions. All cells were authenticated 
according to ANSI/ATCC standard ASN-0002 and routinely tested and confirmed as 
mycoplasm free.   
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3.5.4 GENERATION OF STABLE MDA-MB-231 TRIPZ-SHGRK5 
MDA-MB-231 cells were transduced by Dr. Bojan Ljepoja with the doxycycline-inducible 
TRIPZ-shGRK5 [Clone-ID: V3THS_312367; Sequence: TCGTGAGCAGCATCTTGCA 
(Dharmacon)] construct utilizing a 2nd generation lentiviral system generated with the 
plasmids pCMV-dR8.2 dvpr (Addgene plasmid # 8455) and pCMV-VSV-G (Addgene 
plasmid # 8454) , which were a gift from Bob Weinberg (Stewart et al., 2003). After 
transduction, a 48 h selection with 5 µg/ml puromycin was performed. 
Stimulation of the cells with doxycycline was performed in a concentration of 5 µg/ml 
in DMEM high glucose + 10% FCS for 90 h for mRNA, protein, migration and invasion 
analysis. Medium was replaced with fresh, doxycycline containing medium every 48 h 
to compensate for doxycycline degradation. 
3.5.5 SIRNA TRANSFECTION 
For siRNA transfection 300 000 cells/well were seeded in a 6-well plate and transfected 
at the same time with 5 µl Lipofectamine 3000 and 12.5 pmol siRNA per well. 
siGRK5: SMARTpool: ON-TARGETplus Human GRK5 siRNA (L-004626-02, Dharmacon, 
Lafayette, Colorado, USA) 
scramble control: ON-TARGETplus Non-targeting Pool (D-001810-10, Dharmacon) 
siGRPR: Silencer Select siGRPR s6230 (4392420, Thermo Fisher) 
3.5.6 RNA-LYSIS AND PURIFICATION 
90 h prior to RNA lysis cells were seeded at a confluence of 50% and either transfected 
with siRNA or stimulated with doxycycline. Subsequently cells were harvested using 
RNeasy Mini Kit (Qiagen, Venlo, Netherlands) following the manufacturer’s protocol.  
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3.5.7 CDNA SYNTHESIS 
Upon RNA purification 1000 ng RNA were taken to synthesize cDNA according to 
manufacturer’s protocol using qScript cDNA Synthesis Kit (Quantabio, Beverly. 
Massachusetts, USA). 
3.5.8 QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) 
To analyze the mRNA expression a qPCR was performed using the LightCycler 480 
(Roche, Basel, Switzerland), the Universal Probe Library (UPL, Roche) and LighCycler 
480 Probes Master (Roche). The examined mixture contained 10 µl Probes Master, 4.4 
µl nuclease free water, 0.2 µl left primer (20 µM), 0.2 µl right primer (20 µM), 0.2 µl 
probe and 5 µl cDNA per well. The utilized primer probe pairs are listed below. 
 left primer right primer probe 
GRK5 aagtccatctgcaagatgctg ggggtgtctcttgacctctg # 26 
GRPR cccgtggaagggaatataca gcggtacaggtagatgacatga # 36 
GRP cagccacctcaacccaag tggagcagagagtctaccaactt # 61 
ROCK1 gatcccaaatcggaagtgaa caaatcatataccaaagcatccaa # 42 
CDC42  tggagtgttctgcacttacaca ggctcttcttcggttctgg # 37 
RAC1 ctgatgcaggccatcaagt caggaaatgcattggttgtg # 77 
GAPDH tccactggcgtcttcacc ggcagagatgatgaccctttt # 45 
For quantification the 2-ΔCt or the 2-ΔΔCt method was applied and GAPDH was used as 
an internal standard. 
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3.5.9 PROTEIN LYSIS AND WESTERN BLOT 
Cells were lyzed at 80% confluence or 72h after siRNA transfection with RIPA buffer 
containing 1% Triton X. 30μg protein were separated using a SDS-PAGE and 
subsequently transferred to a nitrocellulose membrane. After one hour blocking with 
TRIS-buffered saline with Tween20 (TBST) containing 3% nonfat dry milk, the blots 
were incubated overnight at 4°C with GRK5-antibody (Millipore, Burlington, 
Massachusetts, USA, cat.nr. 05-466) solution in TBST containing 3% nonfat dry milk, 
followed by several washing steps. Afterwards, membranes were incubated for one 
hour in horseradish peroxidase conjugated anti-mouse (goat anti-mouse-hrp, Sigma 
Aldrich) secondary antibody at room temperature. After additional washing steps, 
detection was performed using enhanced chemiluminscence (ECL, GE Healthcare, 
Chicago, Illinois, USA) on X-ray films (Amersham Hyperfilm ECL, GE Healthcare). The 
α-Tubulin antibody (Sigma Aldrich, cat.nr. T9026) was used as loading control. 
3.5.10 EVALUATION OF CELL VIABILITY AND APOPTOSIS INDUCTION 
To determine the impact of doxycycline and the GRK5 KD on cell viability the CellTiter-
Glo luminescent cell viability assay (Promega, Madison, Wisconsin, USA) was utilized. 
To assess the apoptosis induction upon doxycycline treatment and GRK5 KD the 
Caspase-Glo 3/7 Assay (Promega) was used. 90 h prior to both measurements 3 000 
cells/well of MDA-MB-231 TRIPZ-shGRK5 cells were seeded in 96-well plates and 
treated with the indicated concentrations of doxycycline (N=3).  
3.5.11 PROTEOMICS SAMPLE PREPARATION 
For proteomics analysis 300 000 cells/well were seeded (N = 5) in a 6-well plate and 
stimulated every 48h with 5 µg/ml doxycycline for 90h. Subsequently, cells were 
washed three times with cold PBS and lysed with a buffer containing 8 M urea and 400 
mM ammonium bicarbonate. Ultrasound was used to support cell lysis and finally the 
protein samples were purified using QIA-shredder devices (Qiagen).  
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For reduction, 30 µg of total protein was incubated for 30 min at a final concentration 
of 5 mM dithioerythritol (DTE). Cleaved bisulfide bonds were blocked using 
iodoacetamide (final concentration 15 mM) for 30 min in the dark. After dilution with 
water to a concentration of 1 M urea, proteins were first digested for 4 h with 300 ng 
LysC (FUJIFILM Wako Pure Chemicals, Osaka, Japan) and subsequently digested over 
night with 600 ng porcine trypsin (Promega, Madison, WI, USA) at 37°C. The following 
LC-MS was performed by Dr. Thomas Fröhlich and Dr. Georg J. Arnold. Peptides were 
separated and identified on an Ultimate 3000 (Thermo Scientific, Waltham, MA, USA) 
nano-chromatography system coupled to a QExavtive HF-X instrument (Thermo 
Scientific). 2.5 µg of peptides were dissolved in 15 µl solvent A (0.1 % formic acid in 
water) and transferred to a capillary trap column (PepMap 100 C18, 100 µm x 2 cm, 5 
µM particles, Thermo Scientific). Separation was performed at 250 nL/min (Column: 
PepMap RSLC C18, 75 µm x 50 cm, 2 µm particles, Thermo Scientific) with a 160 min 
gradient from 5 % solvent A to 25 % solvent B (0.1% formic acid in acetonitrile) and 
a subsequent 10 min gradient from 25 % to 40 % solvent B. MS spectra were acquired 
using a top 15 data dependent CID method. Precursor spectra were acquired at a 
resolution 60,000 (mass-range: 350-1600) and MS/MS spectra at a resolution of 
15,000. 
3.5.12 MIGRATION AND INVASION ANALYSIS 
For migration and invasion analysis cells were transfected with siRNA or stimulated 
with 5 µg/ml doxycycline 72 h prior to the experiment. Subsequently, 750 µl DMEM 
high glucose supplemented with 0.5% FCS and the indicated ligand was added to the 
lower well of the boyden chamber system Corning BioCoat Matrigel Invasion Chamber 
(Corning, Corning, New York, USA) in the case of invasion analysis and Falcon Cell 
Culture Inserts ([8 µm pores] Coring) in the case of migration analysis. The inserts (N 
= 3) were filled with 500 µl of a cell suspension containing 50 000 cells in DMEM high 
glucose supplemented with 0.5% FCS. 18 h later the cell suspension was removed and 
the inserts were put into 500 µl crystal violet solution containing 20% methanol for at 
least 10 min. Finally, the inserts were washed three times with demineralized water 
and kept overnight at room temperature.  
3. GRK5 REGULATES BREAST CANCER CELL MIGRATION 
69 
DISSERTATION ANN-KATRIN SOMMER 
To determine the amount of migrated / invaded cells five microscopic pictures 
(magnification 10x) of each insert were made (top, bottom, left, right, center) and 
afterwards analyzed using the ImageJ software. 
3.5.13 SUNITINIB TREATMENT 
For cell viability measurement 3 000 MDA-MB-231 cells/well were seeded in triplicates 
in a 96-well plate and treated with the indicated concentrations for 90 h. Afterwards 
the CellTiter-Glo luminescent cell viability assay (Promega) was utilized to measure 
cytotoxicity. To analyze the impact of sunitinib on migration 300 000 cells/well were 
seeded in a 6-well plate and pre-treated with sunitinib at the indicated concentrations 
for 72 h. Subsequently, sunitinib was added to the starvation medium (DMEM + 0.5% 
FCS) for the following boyden chamber experiment. Here, 50 000 cells/well were 
seeded in triplicates to the insert. For gene expression analysis 300 000 MDA-MB-231 
cells/well were seeded in 6-well plates and treated with 1 µM sunitinib for 90 h.  
3.5.14 BIOINFORMATICS 
Statistical significance was calculated utilizing a two-tailed Student’s t-test for the 
comparison of two samples and one-way ANOVA with Dunnett’s Multiple Comparison 
Test or multiple t-tests utilizing two-stage linear step-up procedure of Benjamini, 
Krieger and Yekutieli, for the comparison of several samples with the control. * p < 
0.05, ** p < 0.01, *** p < 0.001 
To process the mass spectrometry (MS) data MaxQuant 1.5.1.0 was applied (Tyanova 
et al., 2015) and the Perseus module was used (Tyanova et al., 2016). For label free 
quantification (LFQ) values of the identified proteins were taken and proteins that were 
only identified by site or potential contaminants were excluded. 
The doxycycline induced (+DOX) and the not induced (-DOX) samples were grouped 
and at least three valid values in each group were necessary to enter further analysis. 
The missing values were replaced from normal distribution using the imputation 
feature of Perseus (width, 0.3; down-shift, 1.8).  
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Subsequently, a gene set enrichment analysis (GSEA) was performed using gsea2-
2.2.3 from the Broad Institute (Cambridge, MA, USA) (Mootha et al., 2003; 
Subramanian et al., 2005). As underlying gene set database, the gene ontology 
biological process (GO_BP) was used (Ashburner et al., 2000). The resulting, 
differentially expressed pathways were grouped in the following categories: 
metabolism, signaling, migration, cell differentiation, transport, cell development, 
immune system, gene expression and cell cycle to allow a comparison of up and down 
regulated signaling cascades. 
In order to elucidate the clinical significance of GRK5 and GRPR in breast cancer 
patients the Kaplan-Meier-Plotter was utilized (Gyorffy et al., 2010) (released 
2018/05/01). This web service allows the evaluation of more than 20,000 genes in 
about 1,800 breast cancer patients. MDA-MB-231 cells represent an example for a 
triple-negative breast cancer with a basal subtype according to its gene expression 
profile. Thus, patients with basal like tumors were analyzed and the filters were set 
accordingly. Distant metastasis free survival (DMFS) was chosen as endpoint as cancer 
cell migration and invasion were of special interest in this study. 
3.6 SUPPLEMENTS 
 
Supplementary figure S3. Western blot analysis of GRK5 protein expression in different breast cancer 
cell lines. Tubulin was used as loading control. 
 
 
3. GRK5 REGULATES BREAST CANCER CELL MIGRATION 
71 
DISSERTATION ANN-KATRIN SOMMER 
 
Supplementary figure S4. Cell viability and apoptosis measurement in MDA-MB-231 TRIPZ-shGRK5 
(a) CellTiter-Glo Luminescent Cell Viability Assay 90h after treatment with 5 µg/ml DOX. (b) Caspase-




Supplementary Figure S5. qPCR analysis of GRPRP and GRK5. Examination of gene expression 72h 
and 96h after siGRPR transfection in MDA-MB-231 cells.
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4. SUMMARY 
In this thesis two major hurdles in treatment of breast cancer were investigated, 
namely the development of chemoresistance as well as the formation of metastases.  
In the first part it was shown that the development of chemoresistance is a rather 
individual process without a predetermined pattern (Sommer et al., 2018). The 
sequential doxorubicin treatment in three independent experiments and the 
subsequent proteomics analysis revealed pathways being involved in resistance 
development namely downregulation of apoptotic signaling pathways and upregulation 
of cell redox homeostasis. Moreover, few proteins with altered expression were 
identified in all three experiments i.e., downregulation of 60s ribosomal export protein 
NMD3 (NMD3) and upregulation of 4F2 cell-surface antigen heavy chain (SLC3A2). To 
further investigate the clinical implication of these two proteins the Kaplan-Meier 
Plotter was used. Thereby it was shown that both alterations negatively impact the 
relapse-free survival of luminal A breast cancer patients. 
Albeit the transferability of in vitro data to clinical settings is limited, the result of this 
study clearly shows how complex the development of chemoresistance is and might 
be even more complex in breast cancer patients. These findings further underline that 
recurrent or persistent tumors might need a different treatment compared to the 
primary tumor and in case of targeted therapy require an additional biomarker test. As 
this procedure is not entirely adopted to the clinical praxis a comprehensive diagnosis 
of residual or recurrent tumor tissue may improve the treatment of breast cancer and 
thus patient outcome. 
The second part of this thesis deals with the role of GRK5 in breast cancer metastases. 
Here, it was shown that GRK5 is mainly expressed in mesenchymal like, triple-negative 
breast cancer cells and that reduced GRK5 levels clearly hamper the migration and 
invasion of breast cancer cells (Sommer et al., 2019). Moreover, a comprehensive 
proteomics approach revealed that pathways being involved in cancer cell migration 
are mainly affected by down-regulation of GRK5. By stimulating the breast cancer cells 
with different GPCR ligands, Bombesin was identified as chemoattractant which loses 
its activity upon GRK5 knock-down.  
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Additional evaluation of the signaling pathway being regulated by GRK5 revealed that 
GRPR – the cellular receptor of Bombesin – is mainly expressed in TNBC cells.  
Furthermore, the mRNA level of GRPR and its endogenous ligand GRP decreases by 
GRK5 knock-down.   Finally, it was observed that a knock-down of GRPR hampers the 
migration of breast cancer cells as well. To evaluate the clinical impact of these findings 
TNBC cells were treated with sunitinib – an approved multi-kinase inhibitor that is 
known to inhibit GRK5. Thereby, it was shown that sunitinib treatment reduces cancer 
cell migration as well as the mRNA levels of GRK5 and GRPR at a non-toxic 
concentration. Additionally, downstream molecules of GRPR – CDC42 and ROCK1 – 
were less expressed upon sunitinib treatment and GRK5 knock-down. By utilizing the 
Kaplan-Meier-Plotter we additionally figured out that the distant metastasis free 
survival decreases with overexpression of GRK5 and GRPR in breast cancer patients 
with basal like tumors. 
With this study a novel signaling pathway that regulates the migration of breast cancer 
cells was identified. In addition to that the clinical impact of GRK5 and GRPR on the 
formation of metastases in basal like tumors was shown. Moreover, an approved drug 
– sunitinib – was found to be able to block this signaling cascade thereby reducing the 
migratory ability of breast cancer cells. Even though clinical trials would be necessary 
to prove the efficacy of sunitinib in TNBC this study gives a first hint how the formation 
of metastases can be overcome and may thus improve patient outcomes.  
Breast cancer is one of the most prevalent and deadliest diseases in women worldwide. 
Therefore, it is very important to further investigate mamma carcinoma in clinical but 
also in pre-clinical settings. This thesis generated further knowledge on the 
development of chemoresistance and the formation of metastases in vitro. These two 
obstacles are still major challenges in the treatment of breast cancer patients and 
worsen their clinical outcome. Thus, each single piece contributing to a better 
understanding of breast cancer may improve future therapeutic options and treatment 
regimen. 
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